|
The Netherlands
|
| | | | |
Not Applicable
|
|
|
(州或其他管辖范围
成立公司或组织) |
| |
(主要标准工业
分类代码号) |
| |
(I.R.S. Employer
识别码) |
|
|
Richard D. Truesdell, Jr.
Leo Borchardt Davis Polk & Wardwell LLP 450 Lexington Avenue New York, New York 10017 +1 (212) 450-4000 |
| |
Paul van der Bijl
NautaDutilh N.V. Beethovenstraat 400 1082 PR Amsterdam The Netherlands +31 (20) 717-1000 |
| |
Nathan Ajiashvili
Alison Haggerty Latham & Watkins LLP 885 Third Avenue New York, New York 10022 +1 (212) 906-1200 |
|
注册费计算
|
| ||||||||||||||||||
拟登记的各类证券的名称
|
| |
Proposed
Maximum Aggregate Offering Price(1)(2) |
| |
Amount of
Registration Fee |
| | | ||||||||||
普通股,每股面值0.12欧元
|
| | | $ | 595,771,558 | | | | | $ | 64,999 | | | | |
| | |
Page
|
| |||
Prospectus Summary
|
| | | | 1 | | |
Risk Factors
|
| | | | 15 | | |
有关前瞻性陈述的告诫声明
|
| | | | 85 | | |
Use of Proceeds
|
| | | | 87 | | |
Dividend Policy
|
| | | | 89 | | |
企业重组
|
| | | | 90 | | |
Capitalization
|
| | | | 91 | | |
Dilution
|
| | | | 92 | | |
选定的合并财务信息
|
| | | | 93 | | |
管理层对财务状况和经营成果的讨论和分析
|
| | | | 95 | | |
Business
|
| | | | 122 | | |
Management
|
| | | | 239 | | |
主要股东
|
| | | | 254 | | |
关联方交易
|
| | | | 256 | | |
股本及公司章程说明
|
| | | | 261 | | |
荷兰公司法与美国公司法比较
|
| | | | 270 | | |
符合未来出售条件的普通股
|
| | | | 283 | | |
Taxation
|
| | | | 285 | | |
Underwriting
|
| | | | 301 | | |
Expenses of the Offering
|
| | | | 308 | | |
Legal Matters
|
| | | | 309 | | |
Experts
|
| | | | 309 | | |
判决的执行
|
| | | | 309 | | |
您可以在哪里找到更多信息
|
| | | | 310 | | |
财务报表索引
|
| | | | F-1 | | |
| | |
For the Years Ended
December 31, |
| |
For the Nine Months Ended
September 30, |
| ||||||||||||||||||
| | |
2018
|
| |
2019
|
| |
2019
|
| |
2020
|
| ||||||||||||
| | |
(单位为千欧元,每股金额除外)
|
| |||||||||||||||||||||
| | | | | | | | | | | | | | |
(unaudited)
|
| |||||||||
营业报表和全面收益(亏损)数据:
|
| | | | | | | | | | | | | | | | | | | | | | | | |
Revenue
|
| | | | 12,871 | | | | | | 17,416 | | | | | | 10,600 | | | | | | 42,830 | | |
Cost of sales
|
| | | | (17,744) | | | | | | (27,983) | | | | | | (18,872) | | | | | | (7,049) | | |
销售和分销费用
|
| | | | (1,085) | | | | | | (1,755) | | | | | | (485) | | | | | | (809) | | |
研发费用
|
| | | | (41,722) | | | | | | (43,242) | | | | | | (30,665) | | | | | | (76,337) | | |
一般和行政费用
|
| | | | (25,289) | | | | | | (48,969) | | | | | | (28,504) | | | | | | (33,147) | | |
Other operating income
|
| | | | 808 | | | | | | 5,587 | | | | | | 3,838 | | | | | | 11,695 | | |
Other operating expenses
|
| | | | (663) | | | | | | (552) | | | | | | (339) | | | | | | (357) | | |
Operating loss
|
| | | | (72,824) | | | | | | (99,498) | | | | | | (64,427) | | | | | | (63,174) | | |
Finance income
|
| | | | 1,968 | | | | | | 833 | | | | | | 3,133 | | | | | | 5,103 | | |
Finance expenses
|
| | | | (275) | | | | | | (1,460) | | | | | | (2,924) | | | | | | (14,519) | | |
Loss before income tax
|
| | | | (71,131) | | | | | | (100,125) | | | | | | (64,218) | | | | | | (72,590) | | |
Income tax benefit (expense)
|
| | | | (110) | | | | | | 252 | | | | | | 335 | | | | | | 1,615 | | |
Net loss
|
| | | | (71,241) | | | | | | (99,873) | | | | | | (63,883) | | | | | | (70,975) | | |
其他综合损益: | | | | | | | | | | | | | | | | | | | | | | | | | |
随后可能重新分类为损益的项目
|
| | | | | | | | | | | | | | | | | | | | | | | | |
外币调整
|
| | | | 66 | | | | | | 32 | | | | | | (20) | | | | | | 76 | | |
Total comprehensive loss
|
| | | | (71,175) | | | | | | (99,841) | | | | | | (63,903) | | | | | | (70,899) | | |
|
| | |
As of September 30, 2020
|
| |||||||||
| | |
Actual
|
| |
Pro Forma(1)(2)
|
| ||||||
| | |
(in thousands of euros)
(unaudited) |
| |||||||||
财务状况数据报表: | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | | 892,399 | | | | | | 1,288,680 | | |
Total assets
|
| | | | 1,021,907 | | | | | | 1,418,188 | | |
Total liabilities
|
| | | | 260,557 | | | | | | 260,557 | | |
Total equity
|
| | | | 761,350 | | | | | | 1,157,631 | | |
| | |
Actual
|
| |
Pro Forma
|
| ||||||
| | |
(in thousands of euros)
(unaudited) |
| |||||||||
现金和现金等价物
|
| | | | 892,399(1) | | | | | | 1,288,680 | | |
Equity: | | | | | | | | | | | | | |
Issued capital
|
| | | | 21,560 | | | | | | 22,160 | | |
Capital reserve
|
| | | | 1,326,766 | | | | | | 1,722,447 | | |
Accumulated deficit
|
| | | | (586,922) | | | | | | (586,922) | | |
其他综合收益
|
| | | | (54) | | | | | | (54) | | |
股东权益合计
|
| | | | 761,350 | | | | | | 1,157,631 | | |
Total capitalization
|
| | | | 761,350 | | | | | | 1,157,631 | | |
| | |
$
|
| |
€
|
| ||||||
假定普通股每股公开发行价
|
| | | | 102.69 | | | | | | 83.69 | | |
截至2020年9月30日的每股普通股历史有形账面净值
|
| | | | 5.11 | | | | | | 4.16 | | |
可归因于此的每股普通股有形账面净值增加
offering |
| | | | 2.49 | | | | | | 2.03 | | |
本次发售生效后,预计2020年9月30日每股普通股的有形账面净值
|
| | | | 7.60 | | | | | | 6.19 | | |
对新投资者的每股普通股摊薄
|
| | | | 95.09 | | | | | | 77.50 | | |
每股普通股对新投资者的摊薄百分比
|
| | | | 92.6% | | | | | | 92.6% | | |
| | |
For the Years Ended
December 31, |
| |
For the Nine Months Ended
September 30, |
| ||||||||||||||||||
| | |
2018
|
| |
2019
|
| |
2019
|
| |
2020
|
| ||||||||||||
| | |
(单位为千欧元,每股金额除外)
|
| |||||||||||||||||||||
| | | | | | | | | | | | | | |
(unaudited)
|
| |||||||||
营业报表和全面收益(亏损)数据:
|
| | | | | | | | | | | | | | | | | | | | | | | | |
Revenue
|
| | | | 12,871 | | | | | | 17,416 | | | | | | 10,600 | | | | | | 42,830 | | |
Cost of sales
|
| | | | (17,744) | | | | | | (27,983) | | | | | | (18,872) | | | | | | (7,049) | | |
销售和分销费用
|
| | | | (1,085) | | | | | | (1,755) | | | | | | (485) | | | | | | (809) | | |
研发费用
|
| | | | (41,722) | | | | | | (43,242) | | | | | | (30,665) | | | | | | (76,337) | | |
一般和行政费用
|
| | | | (25,289) | | | | | | (48,969) | | | | | | (28,504) | | | | | | (33,147) | | |
Other operating income
|
| | | | 808 | | | | | | 5,587 | | | | | | 3,838 | | | | | | 11,695 | | |
其他运营费用
|
| | | | (663) | | | | | | (552) | | | | | | (339) | | | | | | (357) | | |
Operating loss
|
| | | | (72,824) | | | | | | (99,498) | | | | | | (64,427) | | | | | | (63,174) | | |
Finance income
|
| | | | 1,968 | | | | | | 833 | | | | | | 3,133 | | | | | | 5,103 | | |
Finance expenses
|
| | | | (275) | | | | | | (1,460) | | | | | | (2,924) | | | | | | (14,519) | | |
Loss before income tax
|
| | | | (71,131) | | | | | | (100,125) | | | | | | (64,218) | | | | | | (72,590) | | |
所得税优惠(费用)
|
| | | | (110) | | | | | | 252 | | | | | | 335 | | | | | | 1,615 | | |
Net loss
|
| | | | (71,241) | | | | | | (99,873) | | | | | | (63,883) | | | | | | (70,975) | | |
其他综合损益: | | | | | | | | | | | | | | | | | | | | | | | | | |
随后可能重新分类为损益的项目
|
| | | | | | | | | | | | | | | | | | | | | | | | |
外币调整
|
| | | | 66 | | | | | | 32 | | | | | | (20) | | | | | | 76 | | |
全面亏损
|
| | | | (71,175) | | | | | | (99,841) | | | | | | (63,903) | | | | | | (70,899) | | |
|
| | |
As of December 31,
|
| |
As of
September 30, |
| ||||||||||||
| | |
2018
|
| |
2019
|
| |
2020
|
| |||||||||
| | | | | | | | | | | | | | |
(unaudited)
|
| |||
| | |
(in thousands of euros)
|
| |||||||||||||||
财务状况数据报表: | | | | | | | | | | | | | | | | | | | |
现金和现金等价物
|
| | | | 21,380 | | | | | | 30,684 | | | | | | 892,399 | | |
Total assets
|
| | | | 125,659 | | | | | | 130,620 | | | | | | 1,021,907 | | |
Total liabilities
|
| | | | 93,576 | | | | | | 173,422 | | | | | | 260,557 | | |
Total equity
|
| | | | 32,083 | | | | | | (42,802) | | | | | | 761,350 | | |
| | |
For the Nine Months Ended
September 30, |
| |||||||||
| | |
2019
|
| |
2020
|
| ||||||
| | |
(unaudited)
|
| |||||||||
| | |
(in thousands of euros,
except per share data) |
| |||||||||
营业报表和全面收益(亏损)数据: | | | | | | | | | | | | | |
Revenue
|
| | | | 10,600 | | | | | | 42,830 | | |
Cost of sales
|
| | | | (18,872) | | | | | | (7,049) | | |
销售和分销费用
|
| | | | (485) | | | | | | (809) | | |
研发费用
|
| | | | (30,665) | | | | | | (76,337) | | |
一般和行政费用
|
| | | | (28,504) | | | | | | (33,147) | | |
Other operating income
|
| | | | 3,838 | | | | | | 11,695 | | |
其他运营费用
|
| | | | (339) | | | | | | (357) | | |
Operating loss
|
| | | | (64,427) | | | | | | (63,174) | | |
Finance income
|
| | | | 3,133 | | | | | | 5,103 | | |
Finance expenses
|
| | | | (2,924) | | | | | | (14,519) | | |
Loss before income tax
|
| | | | (64,218) | | | | | | (72,590) | | |
所得税优惠(费用)
|
| | | | 335 | | | | | | 1,615 | | |
Net loss
|
| | | | (63,883) | | | | | | (70,975) | | |
其他综合损益: | | | | | | | | | | | | | |
随后可能重新分类为损益的项目
|
| | | | | | | | | | | | |
外币调整
|
| | | | (20) | | | | | | 76 | | |
全面亏损
|
| | | | (63,903) | | | | | | (70,899) | | |
每股净亏损(基本亏损和稀释后亏损)
|
| | | | (0.66) | | | | | | (0.61) | | |
| | |
For the nine months ended
September 30, |
| |||||||||
| | |
2019
|
| |
2020
|
| ||||||
| | |
(in thousands of euros)
(unaudited) |
| |||||||||
Personnel
|
| | | | (7,249) | | | | | | (2,171) | | |
Materials
|
| | | | (4,022) | | | | | | (1,380) | | |
Third-party services
|
| | | | (5,339) | | | | | | (2,432) | | |
Maintenance and lease
|
| | | | (770) | | | | | | (752) | | |
摊销折旧
|
| | | | (1,259) | | | | | | (250) | | |
Other
|
| | | | (233) | | | | | | (64) | | |
Total | | | | | (18,872) | | | | | | (7,049) | | |
| | |
For the nine months ended
September 30, |
| |||||||||
| | |
2019
|
| |
2020
|
| ||||||
| | |
(in thousands of euros)
(unaudited) |
| |||||||||
Personnel
|
| | | | (257) | | | | | | (755) | | |
摊销折旧
|
| | | | (61) | | | | | | (77) | | |
Other
|
| | | | (167) | | | | | | 23 | | |
Total | | | | | (485) | | | | | | (809) | | |
| | |
For the nine months ended
September 30, |
| |||||||||
| | |
2019
|
| |
2020
|
| ||||||
| | |
(in thousands of euros)
(unaudited) |
| |||||||||
Materials
|
| | | | (2,605) | | | | | | (21,595) | | |
Personnel
|
| | | | (9,321) | | | | | | (16,213) | | |
摊销折旧
|
| | | | (895) | | | | | | (2,589) | | |
注册合法权利的专利和费用
|
| | | | (3,143) | | | | | | (3,525) | | |
Third-party services
|
| | | | (14,426) | | | | | | (27,973) | | |
Maintenance and lease
|
| | | | (20) | | | | | | (560) | | |
Other
|
| | | | (255) | | | | | | (3,882) | | |
Total | | | | | (30,665) | | | | | | (76,337) | | |
| | |
For the nine months ended
September 30, |
| |||||||||
| | |
2019
|
| |
2020
|
| ||||||
| | |
(in thousands of euros)
(unaudited) |
| |||||||||
Key Programs (CV8102, CV7202 and CVnCoV) | | | | | | | | | | | | | |
CV8102
|
| | | | 3,871 | | | | | | 5,443 | | |
CV7202
|
| | | | 1,374 | | | | | | 4,474 | | |
CVnCoV
|
| | | | — | | | | | | 27,504 | | |
其他研发项目
|
| | | | 10,126 | | | | | | 9,050 | | |
Unallocated costs(1)
|
| | | | 15,294 | | | | | | 30,864 | | |
Total | | | | | 30,665 | | | | | | 76,337 | | |
| | |
For the nine months ended
September 30, |
| |||||||||
| | |
2019
|
| |
2020
|
| ||||||
| | |
(in thousands of euros)
(unaudited) |
| |||||||||
Personnel
|
| | | | (16,747) | | | | | | (15,847) | | |
维护和租赁成本
|
| | | | (2,138) | | | | | | (1,571) | | |
Third-party services
|
| | | | (4,203) | | | | | | (5,097) | | |
法律和其他专业服务
|
| | | | (825) | | | | | | (2,276) | | |
摊销折旧
|
| | | | (2,709) | | | | | | (4,382) | | |
Other
|
| | | | (1,882) | | | | | | (3,974) | | |
Total | | | | | (28,504) | | | | | | (33,147) | | |
| | |
For the Years Ended
December 31, |
| |||||||||
| | |
2018
|
| |
2019
|
| ||||||
| | |
(单位为千欧元,
除外
per share data) |
| |||||||||
营业报表和全面收益(亏损)数据: | | | | | | | | | | | | | |
Revenue
|
| | | | 12,871 | | | | | | 17,416 | | |
Cost of sales
|
| | | | (17,744) | | | | | | (27,983) | | |
销售和分销费用
|
| | | | (1,085) | | | | | | (1,755) | | |
研发费用
|
| | | | (41,722) | | | | | | (43,242) | | |
一般和行政费用
|
| | | | (25,289) | | | | | | (48,969) | | |
Other operating income
|
| | | | 808 | | | | | | 5,587 | | |
其他运营费用
|
| | | | (663) | | | | | | (552) | | |
Operating loss
|
| | | | (72,824) | | | | | | (99,498) | | |
Finance income
|
| | | | 1,968 | | | | | | 833 | | |
Finance expenses
|
| | | | (275) | | | | | | (1,460) | | |
Loss before income tax
|
| | | | (71,131) | | | | | | (100,125) | | |
所得税优惠(费用)
|
| | | | (110) | | | | | | 252 | | |
Net loss for the year
|
| | | | (71,241) | | | | | | (99,873) | | |
其他综合损益: | | | | | | | | | | | | | |
随后可能重新分类为损益的项目
|
| | | | | | | | | | | | |
外币调整
|
| | | | 66 | | | | | | 32 | | |
本年度全面亏损总额
|
| | | | (71,175) | | | | | | (99,841) | | |
每股净亏损(基本亏损和稀释后亏损)
|
| | | | (0.74) | | | | | | (1.03) | | |
| | |
For the years ended
December 31, |
| |||||||||
| | |
2018
|
| |
2019
|
| ||||||
| | |
(in thousands of euros)
|
| |||||||||
Personnel
|
| | | | (7,703) | | | | | | (9,855) | | |
Materials
|
| | | | (4,941) | | | | | | (7,542) | | |
Third-party services
|
| | | | (2,340) | | | | | | (7,268) | | |
Maintenance and lease
|
| | | | (1,758) | | | | | | (1,060) | | |
摊销折旧
|
| | | | (893) | | | | | | (2,038) | | |
Other
|
| | | | (109) | | | | | | (220) | | |
Total | | | | | (17,744) | | | | | | (27,983) | | |
| | |
For the years ended
December 31, |
| |||||||||
| | |
2018
|
| |
2019
|
| ||||||
| | |
(in thousands of euros)
|
| |||||||||
Personnel
|
| | | | (581) | | | | | | (1,263) | | |
维护和租赁成本
|
| | | | (300) | | | | | | (167) | | |
摊销折旧
|
| | | | (95) | | | | | | (81) | | |
Other
|
| | | | (109) | | | | | | (243) | | |
Total | | | | | (1,085) | | | | | | (1,755) | | |
| | |
For the years ended
December 31, |
| |||||||||
| | |
2018
|
| |
2019
|
| ||||||
| | |
(in thousands of euros)
|
| |||||||||
Materials
|
| | | | (5,867) | | | | | | (4,015) | | |
Personnel
|
| | | | (7,565) | | | | | | (14,385) | | |
摊销折旧
|
| | | | (1,143) | | | | | | (474) | | |
注册合法权利的专利和费用
|
| | | | (4,847) | | | | | | (4,551) | | |
Third-party services
|
| | | | (19,921) | | | | | | (18,626) | | |
Maintenance and lease
|
| | | | (1,156) | | | | | | (670) | | |
Other
|
| | | | (1,223) | | | | | | (521) | | |
Total | | | | | (41,722) | | | | | | (43,242) | | |
| | |
For the years ended
December 31, |
| |||||||||
| | |
2018
|
| |
2019
|
| ||||||
| | |
(in thousands of euros)
|
| |||||||||
Key Programs (CV8102 and CV7202) | | | | | | | | | | | | | |
CV8102
|
| | | | (1,525) | | | | | | (4,511) | | |
CV7202
|
| | | | (1,987) | | | | | | (2,236) | | |
其他研发项目
|
| | | | (14,047) | | | | | | (14,271) | | |
Unallocated costs(1)
|
| | | | (24,163) | | | | | | (22,224) | | |
Total | | | | | (41,722) | | | | | | (43,242) | | |
| | |
For the years ended
December 31, |
| |||||||||
| | |
2018
|
| |
2019
|
| ||||||
| | |
(in thousands of euros)
|
| |||||||||
Personnel
|
| | | | (10,084) | | | | | | (31,645) | | |
维护和租赁成本
|
| | | | (3,239) | | | | | | (4,604) | | |
Third-party services
|
| | | | (4,006) | | | | | | (5,970) | | |
法律和其他专业服务
|
| | | | (4,078) | | | | | | (2,110) | | |
摊销折旧
|
| | | | (1,635) | | | | | | (2,182) | | |
Other
|
| | | | (2,247) | | | | | | (2,458) | | |
Total | | | | | (25,289) | | | | | | (48,969) | | |
| | |
For the nine months ended
September 30, |
| |||||||||
| | |
2019
|
| |
2020
|
| ||||||
| | |
(in thousands of euros)
(unaudited) |
| |||||||||
Net cash flow from (used in): | | | | | | | | | | | | | |
Operating activities
|
| | | | (67,979) | | | | | | 80,982 | | |
Investing activities
|
| | | | 33,047 | | | | | | (17,466) | | |
Financing activities
|
| | | | 48,669 | | | | | | 794,350 | | |
货币换算收益对现金和现金等价物的影响
|
| | | | (139) | | | | | | 3,849 | | |
Overall cash inflow
|
| | | | 13,598 | | | | | | 861,715 | | |
| | |
For the years ended
December 31, |
| |||||||||
| | |
2018
|
| |
2019
|
| ||||||
| | |
(in thousands of euros)
|
| |||||||||
Net cash flow from (used in): | | | | | | | | | | | | | |
Operating activities
|
| | | | (74,110) | | | | | | (86,963) | | |
Investing activities
|
| | | | (4,264) | | | | | | 28,181 | | |
Financing activities
|
| | | | (112) | | | | | | 67,979 | | |
货币换算收益对现金和现金等价物的影响
|
| | | | 213 | | | | | | 107 | | |
整体现金流入(流出)
|
| | | | (78,273) | | | | | | 9,304 | | |
| | |
Payment Due by Period
|
| |||||||||||||||||||||||||||||||||||||||
| | |
Total(2)
|
| |
2021
|
| |
2022
|
| |
2023
|
| |
2024
|
| |
2025
|
| |
Thereafter
|
| |||||||||||||||||||||
| | |
(in thousands of euros)
|
| |||||||||||||||||||||||||||||||||||||||
合同CMO承诺(1)
|
| | | | 97,151 | | | | | | 97,151 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Lease liabilities
|
| | | | 30,087 | | | | | | 2,961 | | | | | | 3,074 | | | | | | 3,131 | | | | | | 3,310 | | | | | | 3,449 | | | | | | 14,161 | | |
长期债务义务
|
| | | | 25,875 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 25,875 | | |
Total
|
| | |
|
153,112
|
| | | |
|
100,112
|
| | | |
|
3,074
|
| | | |
|
3,131
|
| | | |
|
3,310
|
| | | |
|
3,449
|
| | | |
|
30,086
|
| |
至少发生一次事件的患者,n(%)
|
| |
Stratum 1
(n=16) |
| |
Stratum 2
(n=8) |
| |
Stratum 3
(n=2) |
| |
Overall
(n=26) |
| ||||||||||||
TEAE
|
| | | | 16 (100.0) | | | | | | 8 (100.0) | | | | | | 2 (100.0) | | | | | | 26 (100.0) | | |
BI1361849-and/or radiation-related AE
|
| | | | 16 (100.0) | | | | | | 8(100.0) | | | | | | 2(100.0) | | | | | | 26(100.0) | | |
TEAE related to BI1361849
|
| | | | 15(93.8) | | | | | | 8(100.0) | | | | | | 2(100.0) | | | | | | 26(96.2) | | |
与辐射相关的TEAE
|
| | | | 4(25.0) | | | | | | 1(12.5) | | | | | | 0(50.0) | | | | | | 5(19.2) | | |
Serious TEAE
|
| | | | 7(43.8) | | | | | | 3(37.5) | | | | | | 1(50.0) | | | | | | 11(42.3) | | |
与BI1361849和/或辐射相关的严重声发射
|
| | | | 1(6.3) | | | | | | 0 | | | | | | 0 | | | | | | 1(3.8) | | |
Related to BI1361849
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Related to radiation
|
| | | | 1(6.3) | | | | | | 0 | | | | | | 0 | | | | | | 1(3.8) | | |
TEAE toxicity grade ≥ 3(a)
|
| | | | 9(56.3) | | | | | | 4(50.0) | | | | | | 2(100.0) | | | | | | 15(57.7) | | |
BI1361849和/或与辐射相关的AE毒性等级≥3(A)
|
| | | | 2(12.5) | | | | | | 1(12.5) | | | | | | 1(50.0) | | | | | | 4(15.4) | | |
Related to BI1361849
|
| | | | 1(6.3) | | | | | | 1(12.5) | | | | | | 1(50.0) | | | | | | 3(11.5) | | |
Related to radiation
|
| | | | 1(6.3) | | | | | | 0 | | | | | | 0 | | | | | | 1(3.8) | | |
严重的BI1361849和/或与辐射相关的AE毒性等级≥3(A)
|
| | | | 1(6.3) | | | | | | 0 | | | | | | 0 | | | | | | 1(3.8) | | |
Related to BI1361849
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Related to radiation
|
| | | | 1(6.3) | | | | | | 0 | | | | | | 0 | | | | | | 1(3.8) | | |
TEAE导致停产
|
| | | | 4(25.0) | | | | | | 0 | | | | | | 0 | | | | | | 4(15.4) | | |
TEAE毒性等级为≥3,导致停产
|
| | | | 2(12.5) | | | | | | 0 | | | | | | 0 | | | | | | 2(7.7) | | |
TEAE导致中断/剂量修改
|
| | | | 4(25.0) | | | | | | 0 | | | | | | 0 | | | | | | 4(15.4) | | |
TEAE leading to death
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
| | |
个有反应的患者,n(%)[95%可信区间]
|
| |||||||||
Parameter
|
| |
Stratum 1
(n=16) |
| |
Stratum 2
(n=8) |
| |
Stratum 3
(n=2) |
| |
Overall
(n=26) |
|
Response (CR + PR) rate
|
| |
1 (6.3)
|
| |
0
|
| |
0
|
| |
1 (3.8)
|
|
| | |
[0.2-30.2]
|
| |
[0.0-36.9]
|
| |
[0.0-84.2]
|
| |
[0.1-19.6]
|
|
最佳总体反应 | | | | | | | | | | | | | |
CR
|
| |
0
|
| |
0
|
| |
0
|
| |
0
|
|
| | |
[0.0-20.6]
|
| |
[0.0-36.9]
|
| |
[0.0-84.2]
|
| |
[0.0-13.2]
|
|
PR
|
| |
1 (6.3)
|
| |
0
|
| |
0
|
| |
1 (3.8)
|
|
| | |
[0.2-30.2]
|
| |
[0.0-36.9]
|
| |
[0.0-84.2]
|
| |
[0.1-19.6]
|
|
SD
|
| |
8 (50.0)
|
| |
3 (37.5)
|
| |
1 (50.0)
|
| |
12 (46.2)
|
|
| | |
[24.7-75.3]
|
| |
[8.5-75.5]
|
| |
[1.3-98.7]
|
| |
[26.6-66.6]
|
|
PD
|
| |
7 (43.8)
|
| |
4 (50.0)
|
| |
1(50.0)
|
| |
12 (46.2)
|
|
| | |
[19.8-70.1]
|
| |
[15.7-84.3]
|
| |
[1.3-98.7]
|
| |
[26.6-66.6]
|
|
NE
|
| |
0
|
| |
1 (12.5)
|
| |
0
|
| |
1 (3.8)
|
|
| | |
[0.0-20.6]
|
| |
[0.3-52.7]
|
| |
[0.0-84.2]
|
| |
[0.1-19.6]
|
|
Location
|
| |
Area
(Approximate Sq. Feet) |
| |||
Germany: | | | | | | | |
Tübingen
|
| | | | 189,000 | | |
Frankfurt am Main
|
| | | | 8,600 | | |
Total
|
| | | | 197,600 | | |
United States: | | | | | | | |
Boston
|
| | | | 12,900 | | |
Total
|
| | | | 12,900 | | |
Total
|
| | | | 210,500 | | |
Name
|
| |
Age
|
| |
Term Served
|
| |
Year in which
Term Expires |
| |
Position
|
|
Franz-Werner Haas,LLD,LLM | | | 51 | | |
6/2020 – Present
|
| | 2022 | | | 首席执行官 | |
Florian von der Mülbe, Ph.D., MBA
|
| | 48 | | |
9/2015 – Present
|
| | 2023 | | | 首席生产官 | |
Mariola Fotin-Mleczek博士 | | | 53 | | |
9/2015 – Present
|
| | 2023 | | | 首席技术官 | |
Pierre Kemula, B.Sc. | | | 47 | | |
11/2016 – Present
|
| | 2021 | | | 首席财务官 | |
Antony Blanc, Ph.D.(1) | | | 52 | | |
12/2020 – Present
|
| | 2023 | | |
Chief Business Officer /
首席商务官
|
|
Bernd Winterhalter, MD, Ph.D.(2) | | | 62 | | |
6/2018 – Present
|
| | Not Defined | | |
首席开发官
(Interim)
|
|
Igor Splawski, Ph.D., MSc | | | 52 | | |
7/2020 – Present
|
| | 2023 | | | 首席科学官 | |
Name
|
| |
Age
|
| |
Term Served
|
| |
Year in
which Term Expires |
| |
Functions
|
|
Jean Stéphenne男爵,MBA硕士 | | |
71
|
| |
8/2015 – Present
|
| |
2024
|
| |
董事长兼监事
Director |
|
Ralf Clemens, MD, Ph.D. | | |
68
|
| |
8/2015 – Present
|
| |
2024
|
| | 监管董事 | |
Mathias Hothum, Ph.D. | | |
53
|
| |
8/2015 – Present
|
| |
2024
|
| | 监管董事 | |
汉斯·克里斯托弗·坦纳博士 | | |
69
|
| |
8/2015 – Present
|
| |
2024
|
| | 监管董事 | |
弗里德里希·冯·博伦和哈尔巴赫博士 | | |
58
|
| |
8/2015 – Present
|
| |
2022
|
| |
副董事长兼监事
Director
|
|
Timothy M. Wright, MD | | |
65
|
| |
6/2019 – Present
|
| |
2022
|
| | 监管董事 | |
Craig A. Tooman, MBA | | |
55
|
| |
6/2019 – Present
|
| |
2022
|
| | 监管董事 | |
Viola Bronsema, Ph.D. | | |
57
|
| |
8/2020 – Present
|
| |
2024
|
| | 监管董事 | |
Name
|
| |
Fixed
Compensation (€) |
| |
Attendance
Fees (€) |
| |
Total
Compensation (€) |
| |||||||||
Baron Jean Stéphenne
|
| | | | 102,747 | | | | | | — | | | | | | 102,747 | | |
Ralf Clemens
|
| | | | 55,000 | | | | | | 27,500 | | | | | | 82,500 | | |
Mathias Hothum
|
| | | | 55,000 | | | | | | 27,500 | | | | | | 82,500 | | |
Hans Cristoph Tanner
|
| | | | 55,000 | | | | | | 27,500 | | | | | | 82,500 | | |
弗里德里希·冯·博伦和哈尔巴赫
|
| | | | 55,000 | | | | | | — | | | | | | 55,000 | | |
Ingmar Hoerr(1)
|
| | | | 21,301 | | | | | | — | | | | | | 21,301 | | |
Timothy M. Wright
|
| | | | 55,000 | | | | | | — | | | | | | 55,000 | | |
Craig A. Tooman
|
| | | | 55,000 | | | | | | — | | | | | | 55,000 | | |
维奥拉·勃朗塞玛博士(2)
|
| | | | 20,644 | | | | | | — | | | | | | 20,644 | | |
Name
|
| |
Number of
Shares |
| |
Percentage
of Shares Outstanding |
| |
Voting
Rights |
| |||||||||
Baron Jean Stéphenne
|
| | | | — | | | | | | — | | | | | | — | | |
Ralf Clemens
|
| | | | — | | | | | | — | | | | | | — | | |
Mathias Hothum
|
| | | | — | | | | | | — | | | | | | — | | |
Hans Cristoph Tanner
|
| | | | 188,172 | | | | | | 0.1% | | | | | | — | | |
弗里德里希·冯·博伦和哈尔巴赫
|
| | | | 241,935 | | | | | | 0.1% | | | | | | — | | |
Ingmar Hoerr(1)
|
| | | | 1,129,165 | | | | | | 0.63% | | | | | | — | | |
Timothy M. Wright
|
| | | | — | | | | | | — | | | | | | — | | |
Craig A. Tooman
|
| | | | — | | | | | | — | | | | | | — | | |
维奥拉·勃朗塞玛博士(2)
|
| | | | — | | | | | | — | | | | | | — | | |
Name
|
| |
Number
of Options |
| |
Title
|
| |
Amount
of Securities (€) |
| |
Exercise
Price (€) |
| |
Purchase
Price (€) |
| |
Expiration Date
|
| |||||||||||||||
Baron Jean Stéphenne
|
| | | | — | | | |
—
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Ralf Clemens
|
| | | | — | | | |
—
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Mathias Hothum
|
| | | | — | | | |
—
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Hans Cristoph Tanner
|
| | | | — | | | |
—
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
弗里德里希·冯·博伦和哈尔巴赫
|
| | | | — | | | |
—
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Ingmar Hoerr(1)
|
| | | | 369,423 | | | |
Share Option
Awards |
| | | | 369,423 | | | | | | 1.00 | | | | | | 2,776 | | | | | | 12/31/2021 | | |
Timothy M. Wright
|
| | | | — | | | |
—
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Craig A. Tooman
|
| | | | — | | | |
—
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Dr. Viola Bronsema(2)
|
| | | | — | | | |
—
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Name*(9)
|
| |
Salary
(€) |
| |
Bonus(1)
(€) |
| |
All Other
Compensation(2) (€) |
| |
Total
Compensation(3) (€) |
| ||||||||||||
Daniel(L.Menichella)(4)(5)
|
| | | | 129,843 | | | | | | 318,218 | | | | | | 651,025 | | | | | | 1,099,086 | | |
弗洛里安·冯德穆贝
|
| | | | 258,533 | | | | | | 235,375 | | | | | | 25,482 | | | | | | 519,390 | | |
{br]玛丽奥拉·福廷-姆莱策克
|
| | | | 226,866 | | | | | | 221,875 | | | | | | 19,492 | | | | | | 468,233 | | |
弗朗茨-维尔纳·哈斯
|
| | | | 264,866 | | | | | | 312,150 | | | | | | 24,865 | | | | | | 601,881 | | |
皮埃尔·克米拉
|
| | | | 250,199 | | | | | | 235,375 | | | | | | 99,928 | | | | | | 585,502 | | |
贝恩德·温特豪德(7)
|
| | | | 455,955 | | | | | | — | | | | | | — | | | | | | 455,955 | | |
迪米特里斯·沃利奥蒂斯(8)
|
| | | | 11,283 | | | | | | — | | | | | | 306,935 | | | | | | 318,218 | | |
Igor Splawski(10)(11)
|
| | | | 146,883 | | | | | | — | | | | | | 74,154 | | | | | | 220,037 | | |
Name*
|
| |
Number of
Shares |
| |
Percentage
of Shares Outstanding |
| |
Voting
Rights |
| |||||||||
Daniel L. Menichella(1)
|
| | | | — | | | | | | — | | | | | | — | | |
Florian von der Mulbe
|
| | | | 820,025 | | | | | | 0.45% | | | | | | — | | |
Mariola Fotin-Mleczek
|
| | | | — | | | | | | — | | | | | | — | | |
Franz-Werner Haas
|
| | | | — | | | | | | — | | | | | | — | | |
Name*
|
| |
Number of
Shares |
| |
Percentage
of Shares Outstanding |
| |
Voting
Rights |
| |||||||||
Pierre Kemula
|
| | | | — | | | | | | — | | | | | | — | | |
Bernd Winterhalter(2)
|
| | | | — | | | | | | — | | | | | | — | | |
Dimitris Voliotis
|
| | | | — | | | | | | — | | | | | | — | | |
Igor Splawski(3)
|
| | | | — | | | | | | — | | | | | | — | | |
Name*
|
| |
Number of
Options |
| |
Title
|
| |
Amount
of Securities (€) |
| |
Exercise
Price (€) |
| |
Purchase
Price (€) |
| |
Expiration
Date |
| |||||||||
Daniel Menichella(1)
|
| | | | — | | | |
—
|
| | | | — | | | |
—
|
| |
—
|
| | | | — | | |
Florian von der Mulbe
|
| | | | 268,417 | | | |
Share Option Awards
|
| | | | 268,417 | | | |
1.00
|
| |
2,017
|
| | | | 12/31/2021 | | |
Mariola Fotin-Mleczek
|
| | | | — | | | |
—
|
| | | | — | | | |
—
|
| |
—
|
| | | | — | | |
Franz-Werner Haas
|
| | | | — | | | |
—
|
| | | | — | | | |
—
|
| |
—
|
| | | | — | | |
Pierre Kemula
|
| | | | — | | | |
—
|
| | | | — | | | |
—
|
| |
—
|
| | | | — | | |
Bernd Winterhalter(2)
|
| | | | — | | | |
—
|
| | | | — | | | |
—
|
| |
—
|
| | | | — | | |
Dimitris Voliotis
|
| | | | — | | | |
—
|
| | | | — | | | |
—
|
| |
—
|
| | | | — | | |
Igor Splawski(3)(4)
|
| | | | 266,155 | | | |
LTIP Option Awards
|
| | | | 266,155 | | | |
10.04
|
| |
—
|
| | | | 7/14/2030 | | |
Name
|
| |
Program
|
| |
VS
Points Granted |
| |
Max
Vested Points |
| |
Start of
Vesting Period (Only for New Participants) |
| |
Grant date
(Date of Allocation Letter) |
| |
Vesting
Period |
| |
VSOP
Plan |
| |
Valid
until |
| |||||||||||||||||||||
Florian von der Mulbe
|
| | | | VS | | | | | | 103,534 | | | | | | 103,534 | | | | | | | | | | | | 01.01.2009 | | | | | | 36 | | | |
Prior VSOP
|
| | | | 31.12.2025 | | |
Florian von der Mulbe
|
| | | | VS | | | | | | 463,908 | | | | | | 463,908 | | | | | | | | | | | | 01.01.2011 | | | | | | 36 | | | |
Prior VSOP
|
| | | | 31.12.2025 | | |
Florian von der Mulbe
|
| | | | VS | | | | | | 97,944 | | | | | | 97,944 | | | | | | | | | | | | 01.01.2013 | | | | | | 36 | | | |
Prior VSOP
|
| | | | 31.12.2025 | | |
Florian von der Mulbe
|
| | | | VS | | | | | | 202,543 | | | | | | 202,543 | | | | | | | | | | | | 01.01.2015 | | | | | | 12 | | | |
Prior VSOP
|
| | | | 31.12.2025 | | |
Florian von der Mulbe
|
| | | | VS | | | | | | 811,774 | | | | | | 811,774 | | | | | | | | | | | | 11.12.2015 | | | | | | 12 | | | |
Prior VSOP
IPO only
|
| | | | 31.12.2025 | | |
Mariola Fotin-Mleczek
|
| | | | VS | | | | | | 42,051 | | | | | | 42,051 | | | | | | | | | | | | 01.01.2009 | | | | | | 60 | | | |
Prior VSOP
|
| | | | 31.12.2025 | | |
Mariola Fotin-Mleczek
|
| | | | VS | | | | | | 33,268 | | | | | | 33,268 | | | | | | | | | | | | 01.01.2013 | | | | | | 36 | | | |
Prior VSOP
|
| | | | 31.12.2025 | | |
Mariola Fotin-Mleczek
|
| | | | VS | | | | | | 33,268 | | | | | | 33,268 | | | | | | | | | | | | 01.01.2014 | | | | | | 36 | | | |
Prior VSOP
|
| | | | 31.12.2025 | | |
Mariola Fotin-Mleczek
|
| | | | VS | | | | | | 33,268 | | | | | | 33,268 | | | | | | | | | | | | 01.01.2015 | | | | | | 36 | | | |
Prior VSOP
|
| | | | 31.12.2025 | | |
Mariola Fotin-Mleczek
|
| | | | VS | | | | | | 309,671 | | | | | | 309,671 | | | | | | | | | | | | 01.01.2015 | | | | | | 12 | | | |
Prior VSOP
|
| | | | 31.12.2025 | | |
Ulrike Gnad-Vogt
|
| | | | VS | | | | | | 90,751 | | | | | | 90,751 | | | | | | | | | | | | 01.07.2011 | | | | | | 60 | | | |
Prior VSOP
|
| | | | 31.12.2025 | | |
Ulrike Gnad-Vogt
|
| | | | VS | | | | | | 33,268 | | | | | | 33,268 | | | | | | | | | | | | 01.01.2013 | | | | | | 36 | | | |
Prior VSOP
|
| | | | 31.12.2025 | | |
Ulrike Gnad-Vogt
|
| | | | VS | | | | | | 33,268 | | | | | | 33,268 | | | | | | | | | | | | 01.01.2014 | | | | | | 36 | | | |
Prior VSOP
|
| | | | 31.12.2025 | | |
Ulrike Gnad-Vogt
|
| | | | VS | | | | | | 33,268 | | | | | | 33,268 | | | | | | | | | | | | 01.01.2015 | | | | | | 36 | | | |
Prior VSOP
|
| | | | 31.12.2025 | | |
Ulrike Gnad-Vogt
|
| | | | VS | | | | | | 260,964 | | | | | | 260,964 | | | | | | | | | | | | 01.01.2015 | | | | | | 12 | | | |
Prior VSOP
|
| | | | 31.12.2025 | | |
Franz-Werner Haas
|
| | | | VS | | | | | | 186,307 | | | | | | 186,307 | | | | | | | | | | | | 01.06.2012 | | | | | | 36 | | | |
Prior VSOP
|
| | | | 31.12.2025 | | |
Franz-Werner Haas
|
| | | | VS | | | | | | 479,079 | | | | | | 479,079 | | | | | | | | | | | | 01.01.2013 | | | | | | 36 | | | |
Prior VSOP
|
| | | | 31.12.2025 | | |
Franz-Werner Haas
|
| | | | VS | | | | | | 202,543 | | | | | | 202,543 | | | | | | | | | | | | 01.01.2015 | | | | | | 12 | | | |
Prior VSOP
|
| | | | 31.12.2025 | | |
Pierre Kemula
|
| | | | VS | | | | | | 665,388 | | | | | | 665,388 | | | | | | 01.10.2016 | | | | | | 18.04.2019 | | | | | | 36 | | | |
Prior VSOP
|
| | | | 31.12.2025 | | |
Daniel Menichella*
|
| | | | * | | | | | | 3,866,308 | | | | | | 3,866,308 | | | | | | 08.01.2017 | | | | | | 14.10.2019 | | | | | | 48 | | | | * | | | | | 08.01.2027 | | |
| | |
Shares Beneficially
Owned Before This Offering |
| |
普通股受益
生效后拥有的 Offering |
| ||||||||||||||||||||||||
| | | | | | | | | | | | | | |
No exercise
of underwriter’s option |
| |
Full exercise
of underwriter’s option |
| ||||||||||||
Shareholder
|
| |
Number
|
| |
Percentage
|
| |
Number
|
| |
Percentage
|
| |
Percentage
|
| |||||||||||||||
5% Shareholders: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Dievini Hopp Biotech Holding GmbH&Co.Kg(1)
|
| | | | 79,775,217 | | | | | | 44.03% | | | | | | 79,775,217 | | | | | | 42.85% | | | | | | 42.68% | | |
OH Beteiligungen GmbH&Co.KG(4)
|
| | | | 79,775,217 | | | | | | 44.03% | | | | | | 79,775,217 | | | | | | 42.85% | | | | | | 42.68% | | |
DH-Capital GmbH & Co. KG(4)
|
| | | | 79,775,217 | | | | | | 44.03% | | | | | | 79,775,217 | | | | | | 42.85% | | | | | | 42.68% | | |
Kreditanstalt毛皮Wiederaufbau(2)
|
| | | | 29,871,441 | | | | | | 16.49% | | | | | | 29,871,441 | | | | | | 16.05% | | | | | | 15.98% | | |
Glaxo Group Limited
|
| | | | 14,935,721 | | | | | | 8.24% | | | | | | 14,935,721 | | | | | | 8.02% | | | | | | 7.99% | | |
Managing Directors: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Florian von der Mulbe, Ph.D., MBA
|
| | | | 1,257,147 | | | | | | *% | | | | | | 1,257,147 | | | | | | *% | | | | | | *% | | |
Mariola Fotin – Mleczek, Ph.D.
|
| | | | 45,887 | | | | | | *% | | | | | | 45,887 | | | | | | *% | | | | | | *% | | |
Franz – Werner Haas, LLD, LLM
|
| | | | 87,527 | | | | | | *% | | | | | | 87,527 | | | | | | *% | | | | | | *% | | |
Pierre Kemula, B.Sc.
|
| | | | 67,273 | | | | | | *% | | | | | | 67,273 | | | | | | *% | | | | | | *% | | |
监事: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Ralf Clemens, MD, Ph.D.
|
| | | | — | | | | | | —% | | | | | | — | | | | | | —% | | | | | | —% | | |
马蒂亚斯·霍瑟姆博士(3)
|
| | | | 79,775,217 | | | | | | 44.03% | | | | | | 79,775,217 | | | | | | 42.85% | | | | | | 42.68% | | |
让·斯蒂芬尼男爵,MBA硕士
|
| | | | — | | | | | | —% | | | | | | — | | | | | | —% | | | | | | —% | | |
| | |
Shares Beneficially
Owned Before This Offering |
| |
普通股受益
生效后拥有的 Offering |
| ||||||||||||||||||||||||
| | | | | | | | | | | | | | |
No exercise
of underwriter’s option |
| |
Full exercise
of underwriter’s option |
| ||||||||||||
Shareholder
|
| |
Number
|
| |
Percentage
|
| |
Number
|
| |
Percentage
|
| |
Percentage
|
| |||||||||||||||
Hans Cristoph Tanner, Ph.D.
|
| | | | 188,172 | | | | | | *% | | | | | | 188,172 | | | | | | *% | | | | | | *% | | |
弗里德里希·冯·博伦和哈尔巴赫博士(3)
|
| | | | 80,017,152 | | | | | | 44.17% | | | | | | 80,017,152 | | | | | | 42.98% | | | | | | 42.81% | | |
Timothy M. Wright, MD
|
| | | | — | | | | | | —% | | | | | | — | | | | | | —% | | | | | | —% | | |
Craig A. Tooman, MBA
|
| | | | — | | | | | | —% | | | | | | — | | | | | | —% | | | | | | —% | | |
全体常务董事和监事长:
|
| | | | 81,663,159 | | | | | | 45.08% | | | | | | 81,663,159 | | | | | | 43.87% | | | | | | 43.69% | | |
Underwriter
|
| |
Number
of Shares |
| |||
BofA Securities, Inc.
|
| |
|
| |||
Jefferies LLC
|
| | | | | | |
Evercore Group L.L.C.
|
| | | | | | |
瑞银证券有限责任公司
|
| | | | | | |
古根海姆证券有限责任公司
|
| | | | | | |
贝伦伯格资本市场有限责任公司
|
| | | | | | |
Kempen & Co U.S.A., Inc.
|
| | | | | | |
Total
|
| | | | 5,000,000 | | |
| | |
Per Share
|
| |
Without Option
|
| |
With Option
|
| |||||||||
Public offering price
|
| | | $ | | | | | $ | | | | | $ | | | |||
承保折扣
|
| | | $ | | | | | $ | | | | | $ | | | |||
未扣除费用的收益给我们
|
| | | $ | | | | | $ | | | | | $ | | | |
Expenses
|
| |
Amount
|
| |||
美国证券交易委员会注册费
|
| | | $ | 64,999 | | |
FINRA filing fee
|
| | | | 86,750 | | |
印刷费和雕刻费
|
| | | | 175,000 | | |
Legal fees and expenses
|
| | | | 490,840 | | |
会计费和费用
|
| | | | 175,000 | | |
Miscellaneous costs
|
| | | | 55,888 | | |
Total
|
| | | $ | 1,048,477 | | |
| 未经审计的中期简明合并财务报表 - CureVac N.V. | | | | | | | |
|
截至2019年9月30日和2020年9月30日的9个月的中期简明综合经营报表和其他全面收益(亏损)
|
| | | | F-2 | | |
|
截至2019年12月31日和2020年9月30日的中期简明综合财务状况表
|
| | | | F-3 | | |
|
截至2019年9月30日和2020年9月30日止九个月的中期简明综合股东权益变动表
|
| | | | F-4 | | |
|
截至2019年9月30日和2020年9月30日的9个月中期简明合并现金流量表
|
| | | | F-5 | | |
|
截至2019年9月30日及2020年9月30日止九个月未经审核中期简明综合财务报表附注
|
| | | | F-6 | | |
| 合并财务报表 - CureVac AG | | | | | | | |
|
独立注册会计师事务所报告
|
| | | | F-17 | | |
|
截至2018年12月31日和2019年12月31日的合并经营报表和其他全面收益(亏损)
|
| | | | F-18 | | |
|
截至2018年12月31日和2019年12月31日的合并财务状况报表
|
| | | | F-19 | | |
|
截至2018年12月31日和2019年12月31日止年度股东权益变动表
|
| | | | F-20 | | |
|
截至2018年12月31日和2019年12月31日的年度合并现金流量表
|
| | | | F-21 | | |
|
截至2018年12月31日和2019年12月31日止年度合并财务报表附注
|
| | | | F-22 | | |
| | | | | | | | |
Nine Months ended
September 30, |
| |||||||||
| | |
Note
|
| |
2019
|
| |
2020
|
| |||||||||
(单位为千欧元,每股除外)
|
| | | | | | | |
(unaudited)
|
| |||||||||
Revenue
|
| | | | 3.1 | | | | | | 10,600 | | | | | | 42,830 | | |
Cost of sales
|
| | | | 3.2 | | | | | | (18,872) | | | | | | (7,049) | | |
销售和分销费用
|
| | | | 3.3 | | | | | | (485) | | | | | | (809) | | |
研发费用
|
| | | | 3.4 | | | | | | (30,665) | | | | | | (76,337) | | |
一般和行政费用
|
| | | | 3.5 | | | | | | (28,504) | | | | | | (33,147) | | |
Other operating income
|
| | | | 3.6 | | | | | | 3,838 | | | | | | 11,695 | | |
其他运营费用
|
| | | | | | | | | | (339) | | | | | | (357) | | |
Operating loss
|
| | | | | | | | | | (64,427) | | | | | | (63,174) | | |
Finance income
|
| | | | | | | | | | 3,133 | | | | | | 5,103 | | |
Finance expenses
|
| | | | | | | | | | (2,924) | | | | | | (14,519) | | |
Loss before income tax
|
| | | | | | | | | | (64,218) | | | | | | (72,590) | | |
所得税优惠/(费用)
|
| | | | | | | | | | 335 | | | | | | 1,615 | | |
Net loss for the period
|
| | | | | | | | | | (63,883) | | | | | | (70,975) | | |
其他综合收益: | | | | | | | | | | | | | | | | | | | |
随后可能重新分类为损益的项目 | | | | | | | | | | | | | | | | | | | |
外币调整
|
| | | | | | | | | | (20) | | | | | | 76 | | |
本期综合亏损总额
|
| | | | | | | | | | (63,903) | | | | | | (70,899) | | |
每股净亏损(基本和稀释后)*
|
| | | | | | | | | | (0.66) | | | | | | (0.61) | | |
| | |
Note
|
| |
December 31,
2019 |
| |
September 30,
2020 |
| |||||||||
(in thousands of EUR)
|
| | | | | | | | | | | | | |
(unaudited)
|
| |||
Assets | | | | | | | | | | | | | | | | | | | |
Non-current assets | | | | | | | | | | | | | | | | | | | |
Intangible assets
|
| | | | 6.1 | | | | | | 5,698 | | | | | | 10,138 | | |
财产、厂房和设备
|
| | | | 6.2 | | | | | | 48,075 | | | | | | 59,364 | | |
Right-of-use assets
|
| | | | 6.3 | | | | | | 13,611 | | | | | | 34,693 | | |
Other assets
|
| | | | 6.4 | | | | | | 6,061 | | | | | | 2,147 | | |
Deferred tax assets
|
| | | | | | | | | | — | | | | | | 65 | | |
非流动资产合计
|
| | | | | | | | | | 73,445 | | | | | | 106,407 | | |
Current assets | | | | | | | | | | | | | | | | | | | |
Inventories
|
| | | | 8 | | | | | | 6,197 | | | | | | 1,426 | | |
Trade receivables
|
| | | | | | | | | | 15,690 | | | | | | — | | |
Contract assets
|
| | | | | | | | | | 1,463 | | | | | | 535 | | |
Other financial assets
|
| | | | 9 | | | | | | 1,458 | | | | | | 1,129 | | |
预付费用和其他资产
|
| | | | 7 | | | | | | 1,683 | | | | | | 20,011 | | |
现金和现金等价物
|
| | | | | | | | | | 30,684 | | | | | | 892,399 | | |
Total current assets
|
| | | | | | | | | | 57,175 | | | | | | 915,500 | | |
Total assets
|
| | | | | | | | | | 130,620 | | | | | | 1,021,907 | | |
股权和负债 | | | | | | | | | | | | | | | | | | | |
Equity
|
| | | | 4 | | | | | | | | | | | | | | |
Issued capital*
|
| | | | | | | | | | 11,603 | | | | | | 21,560 | | |
Capital reserve*
|
| | | | | | | | | | 461,520 | | | | | | 1,326,766 | | |
Accumulated deficit
|
| | | | | | | | | | (515,947) | | | | | | (586,922) | | |
其他综合收益
|
| | | | | | | | | | 22 | | | | | | (54) | | |
Total equity
|
| | | | | | | | | | (42,802) | | | | | | 761,350 | | |
非流动负债 | | | | | | | | | | | | | | | | | | | |
Convertible loans
|
| | | | 11 | | | | | | 65,018 | | | | | | — | | |
Lease liabilities
|
| | | | | | | | | | 12,126 | | | | | | 27,724 | | |
Contract liabilities
|
| | | | 3.1 | | | | | | 66,040 | | | | | | 121,778 | | |
递延纳税义务
|
| | | | | | | | | | 1,623 | | | | | | — | | |
Other liabilities
|
| | | | | | | | | | 530 | | | | | | 530 | | |
非流动负债合计
|
| | | | | | | | | | 145,336 | | | | | | 150,032 | | |
流动负债 | | | | | | | | | | | | | | | | | | | |
Lease liabilities
|
| | | | | | | | | | 2,004 | | | | | | 2,921 | | |
Trade and other payables
|
| | | | 10 | | | | | | 6,475 | | | | | | 50,225 | | |
Other liabilities
|
| | | | | | | | | | 12,015 | | | | | | 27,052 | | |
Income taxes payable
|
| | | | | | | | | | 111 | | | | | | 130 | | |
Contract liabilities
|
| | | | 3.1 | | | | | | 7,481 | | | | | | 30,197 | | |
流动负债总额
|
| | | | | | | | | | 28,086 | | | | | | 110,525 | | |
Total liabilities
|
| | | | | | | | | | 173,422 | | | | | | 260,557 | | |
权益和负债合计
|
| | | | | | | | | | 130,620 | | | | | | 1,021,907 | | |
(in thousands of EUR)
|
| |
Issued
capital* |
| |
Capital
reserve* |
| |
Accumulated
deficit |
| |
Currency
translation reserve |
| |
Total
equity |
| |||||||||||||||
Balance as of January 1, 2020
|
| | | | 11,603 | | | | | | 461,520 | | | | | | (515,947) | | | | | | 22 | | | | | | (42,802) | | |
Net loss
|
| | | | — | | | | | | — | | | | | | (70,975) | | | | | | — | | | | | | (70,975) | | |
其他综合收益(亏损)
|
| | | | — | | | | | | — | | | | | | — | | | | | | (76) | | | | | | (76) | | |
综合收益(亏损)合计
|
| | |
|
—
|
| | | |
|
—
|
| | | | | (70,975) | | | | | | (76) | | | | | | (71,051) | | |
股份支付费用
|
| | | | — | | | | | | 7,399 | | | | | | — | | | | | | — | | | | | | 7,399 | | |
可转换贷款的权益部分(税后净额)
|
| | | | — | | | | | | 87 | | | | | | — | | | | | | — | | | | | | 87 | | |
Exercise of options
|
| | | | 288 | | | | | | (288) | | | | | | — | | | | | | — | | | | | | — | | |
发行股本(扣除交易成本)
|
| | | | 9,669 | | | | | | 858,048 | | | | | | — | | | | | | — | | | | | | 867,717 | | |
截至2020年9月30日的余额(未经审计)
|
| | | | 21,560 | | | | | | 1,326,766 | | | | | | (586,922) | | | | | | (54) | | | | | | 761,350 | | |
(in thousands of EUR)
|
| |
Issued
capital* |
| |
Capital
reserve* |
| |
Accumulated
deficit |
| |
Currency
translation reserve |
| |
Total
equity |
| |||||||||||||||
Balance as of January 1, 2019
|
| | | | 11,603 | | | | | | 436,564 | | | | | | (416,074) | | | | | | (10) | | | | | | 32,083 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | (64,671) | | | | | | — | | | | | | (64,671) | | |
其他综合收益
|
| | | | — | | | | | | — | | | | | | — | | | | | | 21 | | | | | | 21 | | |
综合收益(亏损)合计
|
| | |
|
—
|
| | | |
|
—
|
| | | | | (64,671) | | | | | | 21 | | | | | | (64,650) | | |
股份支付费用
|
| | | | — | | | | | | 6,073 | | | | | | — | | | | | | — | | | | | | 6,073 | | |
可转换贷款的权益部分(税后净额)
|
| | | | — | | | | | | 5,744 | | | | | | — | | | | | | — | | | | | | 5,744 | | |
截至2019年9月30日的余额(未经审计)
|
| | | | 11,603 | | | | | | 448,381 | | | | | | (480,745) | | | | | | 11 | | | | | | (20,750) | | |
| | |
Nine months ended
September 30, |
| |||||||||
| | |
2019
|
| |
2020
|
| ||||||
(in thousands of EUR)
|
| |
(unaudited)
|
| |||||||||
经营活动 | | | | | | | | | | | | | |
Loss before income tax
|
| | |
|
(64,218)
|
| | | |
|
(72,590)
|
| |
将税前亏损与净现金流对账的调整 | | | | | | | | | | | | | |
Finance income
|
| | | | (3,133) | | | | | | (5,103) | | |
Finance expense
|
| | | | 2,924 | | | | | | 14,519 | | |
折旧及摊销
|
| | | | 4,924 | | | | | | 7,244 | | |
固定资产处置损失
|
| | | | 46 | | | | | | 357 | | |
股份支付费用
|
| | | | 6,074 | | | | | | 7,399 | | |
营运资金变动 | | | | | | | | | | | | | |
贸易应收账款和合同资产减少/(增加)
|
| | | | 1,707 | | | | | | 16,662 | | |
库存减少/(增加)
|
| | | | (4,442) | | | | | | 4,775 | | |
预付费用和其他资产减少/(增加)
|
| | | | (765) | | | | | | (19,336) | | |
来自政府机构和类似机构的赠款收据
|
| | | | 2,178 | | | | | | 17,630 | | |
(减少)/贸易及其他应付款和合同负债增加
|
| | | | (11,912) | | | | | | 116,457 | | |
递延税金减少/(增加)
|
| | | | (312) | | | | | | (65) | | |
(减少)/其他流动财务和其他负债增加
|
| | | | (417) | | | | | | — | | |
Income taxes paid
|
| | | | — | | | | | | (98) | | |
Interest paid
|
| | | | (633) | | | | | | (6,869) | | |
经营活动提供(用于)的净现金流量
|
| | | | (67,979) | | | | | | 80,982 | | |
投资活动 | | | | | | | | | | | | | |
购置房产、厂房和设备
|
| | | | (6,629) | | | | | | (15,149) | | |
购买无形资产
|
| | | | (681) | | | | | | (5,883) | | |
与资产相关的赠款收益
|
| | | | 1,501 | | | | | | 3,237 | | |
出售其他金融资产的收益
|
| | | | 38,856 | | | | | | 329 | | |
投资活动提供(用于)的净现金流
|
| | | | 33,047 | | | | | | (17,466) | | |
融资活动 | | | | | | | | | | | | | |
租赁债务付款
|
| | | | (1,331) | | | | | | (3,478) | | |
股票发行收益(扣除交易成本)
|
| | | | — | | | | | | 867,717 | | |
可转换贷款收益
|
| | | | 50,000 | | | | | | 24,860 | | |
偿还可转换贷款
|
| | | | — | | | | | | (94,749) | | |
融资活动提供的净现金流
|
| | | | 48,669 | | | | | | 794,350 | | |
现金和现金等价物的货币兑换收益(损失)
|
| | | | (139) | | | | | | 3,849 | | |
现金和现金等价物增加
|
| | | | 13,737 | | | | | | 857,867 | | |
期初现金和现金等价物
|
| | | | 21,750 | | | | | | 30,684 | | |
现金和现金等价物,期末
|
| | | | 35,348 | | | | | | 892,399 | | |
| | |
Nine months ended
September 30, |
| |||||||||
| | |
2019
|
| |
2020
|
| ||||||
| | |
EUR k
|
| |
EUR k
|
| ||||||
United States | | | | | | | | | | | | | |
Eli Lilly and Company
|
| | | | 8,694 | | | | | | 34,854 | | |
Germany | | | | | | | | | | | | | |
Boehringer Ingelheim
|
| | | | 1,569 | | | | | | 1,418 | | |
Switzerland | | | | | | | | | | | | | |
CRISPR
|
| | | | 337 | | | | | | 618 | | |
Netherlands | | | | | | | | | | | | | |
Genmab
|
| | | | — | | | | | | 1,893 | | |
Belgium | | | | | | | | | | | | | |
GSK
|
| | | | — | | | | | | 4,047 | | |
Total | | | | | 10,600 | | | | | | 42,830 | | |
| | |
Upfront payments
September 30, 2020 |
| |
Upfront
payments included in contract liabilities at |
| |
Upfront
payments included in contract liabilities at |
| |
Revenue recognized
from upfront payments for nine months ended September 30, |
| |||||||||||||||
Customer
|
| |
September 30,
2019 |
| |
September 30,
2020 |
| |
2019
|
| |
2020
|
| |||||||||||||||
| | |
(in thousands)
|
| |
(EUR k)
|
| |
(EUR k)
|
| |
(EUR k)
|
| |||||||||||||||
Eli Lilly
|
| |
USD 50,000 (EUR 42,200)*
|
| | | | 35,733 | | | | | | — | | | | | | 2,637 | | | | | | 34,854 | | |
CRISPR
|
| | USD 3,000 (EUR 2,524)* | | | | | 1,936 | | | | | | 1,627 | | | | | | 232 | | | | | | 232 | | |
Boehringer Ingelheim
|
| | EUR 30,000 | | | | | 16,336 | | | | | | 14,469 | | | | | | 1,485 | | | | | | 1,400 | | |
Genmab
|
| |
USD 10,000 (EUR 8,937)*
|
| | | | — | | | | | | 7,597 | | | | | | — | | | | | | 1,341 | | |
GSK
|
| | EUR 120,000 | | | | | — | | | | | | 116,255 | | | | | | — | | | | | | 3,718 | | |
Total | | | | | | | | 54,006 | | | | | | 139,948 | | | | | | 4,354 | | | | | | 41,545 | | |
Contract balances:
|
| |
December 31,
2019 |
| |
September 30,
2020 |
| ||||||
| | |
EUR k
|
| |
EUR k
|
| ||||||
Trade receivables
|
| | | | 15,690 | | | | | | — | | |
Contract assets
|
| | | | 1,463 | | | | | | 535 | | |
Contract liabilities
|
| | | | 73,521 | | | | | | 151,975 | | |
| | |
Nine months ended
September 30, |
| |||||||||
| | |
2019
|
| |
2020
|
| ||||||
| | |
EUR k
|
| |
EUR k
|
| ||||||
Personnel
|
| | | | (7,249) | | | | | | (2,171) | | |
Materials
|
| | | | (4,022) | | | | | | (1,380) | | |
Third-party services
|
| | | | (5,339) | | | | | | (2,432) | | |
Maintenance and lease
|
| | | | (770) | | | | | | (752) | | |
摊销折旧
|
| | | | (1,259) | | | | | | (250) | | |
Other
|
| | | | (233) | | | | | | (64) | | |
Total | | | | | (18,872) | | | | | | (7,049) | | |
| | |
Nine months ended
September 30, |
| |||||||||
| | |
2019
|
| |
2020
|
| ||||||
| | |
EUR k
|
| |
EUR k
|
| ||||||
Personnel
|
| | | | (257) | | | | | | (755) | | |
摊销折旧
|
| | | | (61) | | | | | | (77) | | |
Other
|
| | | | (167) | | | | | | 23 | | |
Total | | | | | (485) | | | | | | (809) | | |
| | |
Nine months ended
September 30, |
| |||||||||
| | |
2019
|
| |
2020
|
| ||||||
| | |
EUR k
|
| |
EUR k
|
| ||||||
Materials
|
| | | | (2,605) | | | | | | (21,595) | | |
Personnel
|
| | | | (9,321) | | | | | | (16,213) | | |
摊销折旧
|
| | | | (895) | | | | | | (2,589) | | |
注册合法权利的专利和费用
|
| | | | (3,143) | | | | | | (3,525) | | |
Third-party services
|
| | | | (14,426) | | | | | | (27,973) | | |
Maintenance and lease
|
| | | | (20) | | | | | | (560) | | |
Other
|
| | | | (255) | | | | | | (3,882) | | |
Total | | | | | (30,665) | | | | | | (76,337) | | |
| | |
Nine months ended
September 30, |
| |||||||||
| | |
2019
|
| |
2020
|
| ||||||
| | |
EUR k
|
| |
EUR k
|
| ||||||
Personnel
|
| | | | (16,747) | | | | | | (15,847) | | |
Maintenance and lease
|
| | | | (2,138) | | | | | | (1,571) | | |
Third-party services
|
| | | | (4,203) | | | | | | (5,097) | | |
法律和其他专业服务
|
| | | | (825) | | | | | | (2,276) | | |
摊销折旧
|
| | | | (2,709) | | | | | | (4,382) | | |
Other
|
| | | | (1,882) | | | | | | (3,974) | | |
Total | | | | | (28,504) | | | | | | (33,147) | | |
| | |
Nine months ended
September 30, |
| |||||||||
| | |
2019
|
| |
2020
|
| ||||||
| | |
EUR k
|
| |
EUR k
|
| ||||||
政府机构和类似机构提供的补助金和其他费用报销
|
| | | | 3,781 | | | | | | 11,313 | | |
Other
|
| | | | 57 | | | | | | 382 | | |
Total | | | | | 3,838 | | | | | | 11,695 | | |
| | |
Nine months ended
September 30, |
| ||||||
| | |
2019
|
| |
2020
|
| |||
| | |
EUR k
|
| |
EUR k
|
| |||
研发费用
|
| | | | — | | | |
2,985
|
|
销售和营销费用
|
| | | | — | | | |
467
|
|
一般和行政费用
|
| | | | 6,074 | | | |
3,947
|
|
Total | | | | | 6,074 | | | |
7,399
|
|
| | |
Nine months ended
September 30, |
| |||||||||
Program
|
| |
2019
|
| |
2020
|
| ||||||
| | |
EUR k
|
| |
EUR k
|
| ||||||
前首席执行官格兰特
|
| | | | — | | | | | | 2,551 | | |
New VSOP
|
| | | | — | | | | | | 1,327 | | |
Prior VSOP
|
| | | | 6,074 | | | | | | 3,521 | | |
Total | | | | | 6,074 | | | | | | 7,399 | | |
| | | | | | | | |
Years ended December 31,
|
| |||||||||
(单位为千欧元,每股数据除外)
|
| |
Note
|
| |
2018
|
| |
2019
|
| |||||||||
Revenue
|
| | | | 3.1 | | | | | | 12,871 | | | | | | 17,416 | | |
Cost of sales
|
| | | | 3.2 | | | | | | (17,744) | | | | | | (27,983) | | |
销售和分销费用
|
| | | | 3.3 | | | | | | (1,085) | | | | | | (1,755) | | |
研发费用
|
| | | | 3.4 | | | | | | (41,722) | | | | | | (43,242) | | |
一般和行政费用
|
| | | | 3.5 | | | | | | (25,289) | | | | | | (48,969) | | |
Other operating income
|
| | | | 3.6 | | | | | | 808 | | | | | | 5,587 | | |
其他运营费用
|
| | | | 3.7 | | | | | | (663) | | | | | | (552) | | |
Operating loss
|
| | | | | | | | | | (72,824) | | | | | | (99,498) | | |
Finance income
|
| | | | | | | | | | 1,968 | | | | | | 833 | | |
Finance expenses
|
| | | | | | | | | | (275) | | | | | | (1,460) | | |
Loss before income tax
|
| | | | | | | | | | (71,131) | | | | | | (100,125) | | |
Income tax benefit / (expense)
|
| | | | 14 | | | | | | (110) | | | | | | 252 | | |
Net loss for the year
|
| | | | | | | | | | (71,241) | | | | | | (99,873) | | |
其他综合收益 | | | | | | | | | | | | | | | | | | | |
随后可能重新分类为损益的项目 | | | | | | | | | | | | | | | | | | | |
外币调整
|
| | | | | | | | | | 66 | | | | | | 32 | | |
本年度全面亏损总额
|
| | | | | | | | | | (71,175) | | | | | | (99,841) | | |
每股净亏损(基本和稀释后)*
|
| | | | | | | | | | (0.74) | | | | | | (1.03) | | |
| | | | | | | | |
December 31,
|
| |||||||||
(in thousands of EUR)
|
| |
Note
|
| |
2018
|
| |
2019
|
| |||||||||
Assets | | | | | | | | | | | | | | | | | | | |
Non-current assets | | | | | | | | | | | | | | | | | | | |
Intangible assets
|
| | | | 4 | | | | | | 6,213 | | | | | | 5,698 | | |
财产、厂房和设备
|
| | | | 4 | | | | | | 40,472 | | | | | | 48,075 | | |
Other assets
|
| | | | 4 | | | | | | 5,771 | | | | | | 6,061 | | |
Right-of-use assets
|
| | | | 2 | | | | | | — | | | | | | 13,611 | | |
Deferred tax assets
|
| | | | 14 | | | | | | 133 | | | | | | — | | |
非流动资产合计
|
| | | | | | | | | | 52,589 | | | | | | 73,445 | | |
Current assets | | | | | | | | | | | | | | | | | | | |
Inventories
|
| | | | 5 | | | | | | 2,951 | | | | | | 6,197 | | |
Trade receivables
|
| | | | 3 | | | | | | 5,476 | | | | | | 15,690 | | |
Contract assets
|
| | | | 3 | | | | | | 1,382 | | | | | | 1,463 | | |
Other financial assets
|
| | | | 6 | | | | | | 39,253 | | | | | | 1,458 | | |
预付费用和其他资产
|
| | | | 7 | | | | | | 2,628 | | | | | | 1,683 | | |
现金和现金等价物
|
| | | | | | | | | | 21,380 | | | | | | 30,684 | | |
Total current assets
|
| | | | | | | | | | 73,070 | | | | | | 57,175 | | |
Total assets
|
| | | | | | | | | | 125,659 | | | | | | 130,620 | | |
股权和负债 | | | | | | | | | | | | | | | | | | | |
Equity | | | | | | | | | | | | | | | | | | | |
Issued capital*
|
| | | | | | | | | | 11,610 | | | | | | 11,610 | | |
Capital reserve*
|
| | | | | | | | | | 436,557 | | | | | | 461,513 | | |
Accumulated deficit
|
| | | | | | | | | | (416,074) | | | | | | (515,947) | | |
其他综合收益
|
| | | | | | | | | | (10) | | | | | | 22 | | |
Total equity
|
| | | | 8 | | | | | | 32,083 | | | | | | (42,802) | | |
非流动负债 | | | | | | | | | | | | | | | | | | | |
Convertible loans
|
| | | | 12 | | | | | | — | | | | | | 65,018 | | |
Lease liabilities
|
| | | | 2 | | | | | | — | | | | | | 12,126 | | |
Contract liabilities
|
| | | | 3 | | | | | | 64,583 | | | | | | 66,040 | | |
递延纳税义务
|
| | | | 13 | | | | | | — | | | | | | 1,623 | | |
Other liabilities
|
| | | | | | | | | | 863 | | | | | | 529 | | |
非流动负债合计
|
| | | | | | | | | | 65,446 | | | | | | 145,336 | | |
流动负债 | | | | | | | | | | | | | | | | | | | |
其他财务负债
|
| | | | | | | | | | 77 | | | | | | — | | |
Lease liabilities
|
| | | | 2 | | | | | | — | | | | | | 2,004 | | |
Trade and other payables
|
| | | | 11 | | | | | | 10,913 | | | | | | 6,475 | | |
Other liabilities
|
| | | | 12 | | | | | | 11,146 | | | | | | 12,015 | | |
Income Taxes payable
|
| | | | 13 | | | | | | 217 | | | | | | 111 | | |
Contract liabilities
|
| | | | 3 | | | | | | 5,777 | | | | | | 7,481 | | |
流动负债总额
|
| | | | | | | | | | 28,130 | | | | | | 28,086 | | |
Total liabilities
|
| | | | | | | | | | 93,576 | | | | | | 173,422 | | |
权益和负债合计
|
| | | | | | | | | | 125,659 | | | | | | 130,620 | | |
(in thousands of EUR)
|
| |
Issued
capital* |
| |
Capital
reserve* |
| |
Accumulated
deficit |
| |
Currency
translation reserve |
| |
Total equity
|
| |||||||||||||||
Balance as of January 1, 2018
|
| | | | 11,610 | | | | | | 436,555 | | | | | | (345,320) | | | | | | (76) | | | | | | 102,769 | | |
首次采用IFRS 9的影响
|
| | | | — | | | | | | — | | | | | | (183) | | | | | | — | | | | | | (183) | | |
首次采用IFRS 15的影响
|
| | | | — | | | | | | — | | | | | | 670 | | | | | | — | | | | | | 670 | | |
Adjusted balance as of January 1, 2018
|
| | | | 11,610 | | | | | | 436,555 | | | | | | (344,833) | | | | | | (76) | | | | | | 103,256 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | (71,241) | | | | | | — | | | | | | (71,241) | | |
其他综合收益(亏损)
|
| | | | — | | | | | | — | | | | | | — | | | | | | 66 | | | | | | 66 | | |
综合收益(亏损)合计
|
| | | | — | | | | | | — | | | | | | (71,241) | | | | | | 66 | | | | | | (71,175) | | |
股份支付计划的费用
|
| | | | — | | | | | | 2 | | | | | | — | | | | | | — | | | | | | 2 | | |
Balance as of December 31, 2018
|
| | | | 11,610 | | | | | | 436,557 | | | | | | (416,074) | | | | | | (10) | | | | | | 32,083 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | (99,873) | | | | | | — | | | | | | (99,873) | | |
其他综合收益(亏损)
|
| | | | — | | | | | | — | | | | | | — | | | | | | 32 | | | | | | 32 | | |
综合收益(亏损)合计
|
| | | | — | | | | | | — | | | | | | (99,873) | | | | | | 32 | | | | | | (99,841) | | |
可转换贷款的权益部分
|
| | | | — | | | | | | 7,604 | | | | | | — | | | | | | — | | | | | | 7,604 | | |
可转换贷款的递延税金
|
| | | | — | | | | | | (2,212) | | | | | | — | | | | | | — | | | | | | (2,212) | | |
股份支付计划的费用
|
| | | | — | | | | | | 19,564 | | | | | | — | | | | | | — | | | | | | 19,564 | | |
Balance as of December 31, 2019
|
| | | | 11,610 | | | | | | 461,513 | | | | | | (515,947) | | | | | | 22 | | | | | | (42,802) | | |
| | |
Years ended December 31,
|
| |||||||||
(in thousands of EUR)
|
| |
2018
|
| |
2019
|
| ||||||
经营活动 | | | | | | | | | | | | | |
Loss before income tax
|
| | | | (71,131) | | | | | | (100,125) | | |
将税前亏损与净现金流对账的调整 | | | | | | | | | | | | | |
Finance income
|
| | | | (1,968) | | | | | | (833) | | |
Finance expense
|
| | | | 275 | | | | | | 1,460 | | |
折旧及摊销
|
| | | | 3,781 | | | | | | 7,164 | | |
固定资产处置损失
|
| | | | 52 | | | | | | 241 | | |
股份支付费用
|
| | | | (4,248) | | | | | | 19,564 | | |
营运资金变动 | | | | | | | | | | | | | |
贸易应收账款和合同资产减少/(增加)
|
| | | | (5,595) | | | | | | (10,117) | | |
库存减少/(增加)
|
| | | | 878 | | | | | | (3,246) | | |
其他资产减少/(增加)
|
| | | | (6,106) | | | | | | 630 | | |
来自政府机构和类似机构的赠款收据
|
| | | | 214 | | | | | | 9,304 | | |
(减少)/贸易及其他应付款和合同负债增加
|
| | | | 9,402 | | | | | | (9,584) | | |
(减少)/其他流动财务和其他负债增加
|
| | | | 336 | | | | | | (334) | | |
Income taxes paid
|
| | | | (26) | | | | | | (345) | | |
Interest received
|
| | | | 15 | | | | | | 81 | | |
Interest paid
|
| | | | 11 | | | | | | (824) | | |
经营活动中使用的净现金流量
|
| | | | (74,110) | | | | | | (86,963) | | |
投资活动 | | | | | | | | | | | | | |
购置房产、厂房和设备
|
| | | | (9,406) | | | | | | (11,172) | | |
购买无形资产
|
| | | | (5,317) | | | | | | (1,052) | | |
与资产相关的赠款收益
|
| | | | — | | | | | | 2,325 | | |
来自其他金融资产的收益
|
| | | | 10,459 | | | | | | 38,080 | | |
投资活动产生(用于)的净现金流
|
| | | | (4,264) | | | | | | 28,181 | | |
融资活动 | | | | | | | | | | | | | |
租赁债务付款
|
| | | | (112) | | | | | | (1,910) | | |
可转换贷款收益
|
| | | | — | | | | | | 69,889 | | |
融资活动产生(用于)的净现金流
|
| | | | (112) | | | | | | 67,979 | | |
现金及现金等价物净增(减)
|
| | | | (78,486) | | | | | | 9,197 | | |
货币换算收益对现金和现金等价物的影响
|
| | | | 213 | | | | | | 107 | | |
期初现金和现金等价物
|
| | | | 99,653 | | | | | | 21,380 | | |
现金和现金等价物,期末
|
| | | | 21,380 | | | | | | 30,684 | | |
|
Software and Licenses
|
| |
3 to 8 years
|
|
|
Buildings:
|
| |
1 to 10 years
|
|
|
技术装备和机器:
|
| |
3 to 14 years
|
|
|
其他设备、家具和固定装置:
|
| |
3 to 14 years
|
|
| | |
EUR k
|
| |||
截至2018年12月31日的现有承诺 | | | | | | | |
经营租赁承诺额
|
| | | | 48,008 | | |
融资租赁负债的最低租赁付款(名义金额)
|
| | | | 78 | | |
短期租赁的救济选项
|
| | | | (110) | | |
开始日期在2019年1月1日之后的租约,金额为截至2018年12月31日的现有承诺额
|
| | | | (28,557) | | |
Other
|
| | | | 123 | | |
截至2019年1月1日的租赁总负债
|
| | | | 19,542 | | |
Effect of discounting
|
| | | | (3,655) | | |
Lease liabilities as at January 1, 2019
|
| | | | 15,887 | | |
截至2018年12月31日的融资租赁负债现值
|
| | | | (77) | | |
截至2019年1月1日首次应用IFRS第16号时的租赁负债
|
| | | | 15,810 | | |
截至2019年1月1日的加权平均增量借款利率
|
| | | | 5.64% | | |
|
Land and Buildings:
|
| |
1 to 15 years
|
|
|
Vehicles:
|
| |
3 to 4 years
|
|
|
Other equipment:
|
| |
2 to 5 years
|
|
| | |
Right-of-use assets
|
| |||||||||||||||||||||
| | |
Land and
Buildings |
| |
Vehicles
|
| |
Other
equipment |
| |
Total
|
| ||||||||||||
| | |
EURk
|
| |
EURk
|
| |
EURk
|
| |
EURk
|
| ||||||||||||
As at January 1, 2019
|
| | | | 15,536 | | | | | | 132 | | | | | | 239 | | | | | | 15,907 | | |
Additions
|
| | | | 82 | | | | | | 59 | | | | | | 13 | | | | | | 154 | | |
Depreciation expense
|
| | | | (2,322) | | | | | | (65) | | | | | | (142) | | | | | | (2,529) | | |
外币折算
|
| | | | 79 | | | | | | — | | | | | | — | | | | | | 79 | | |
As at December 31, 2019
|
| | | | 13,375 | | | | | | 126 | | | | | | 110 | | | | | | 13,611 | | |
| | |
EUR k
|
| |||
As at January 1, 2019
|
| | |
|
15,887
|
| |
Additions
|
| | | | 153 | | |
Accretion of interest
|
| | | | 824 | | |
Payments
|
| | | | (2,812) | | |
外币折算
|
| | | | 78 | | |
As at December 31, 2019
|
| | | | 14,130 | | |
Current
|
| | | | 2,004 | | |
Non-current
|
| | | | 12,126 | | |
| | |
EUR k
|
| |||
使用权资产折旧费用
|
| | | | (2,529) | | |
租赁负债利息支出
|
| | | | (824) | | |
与短期租赁有关的费用(包括在销售成本中)
|
| | | | (167) | | |
租赁低价值资产的相关费用(包括在行政费用中)
|
| | | | (94) | | |
确认损益的总金额
|
| | | | (3,614) | | |
| | |
December 31,
2018 |
| |
December 31,
2019 |
| ||||||
| | |
EUR k
|
| |
EUR k
|
| ||||||
United States | | | | | | | | | | | | | |
Eli Lilly and Company
|
| | | | 8,927 | | | | | | 14,319 | | |
Germany | | | | | | | | | | | | | |
Boehringer Ingelheim
|
| | | | 3,337 | | | | | | 2,474 | | |
Others
|
| | | | 5 | | | | | | 104 | | |
Switzerland | | | | | | | | | | | | | |
CRISPR
|
| | | | 602 | | | | | | 519 | | |
Total
|
| | | | 12,871 | | | | | | 17,416 | | |
Customer
|
| |
Upfront payments
received or receivable at December 31, 2019 (in thousands) |
| |
Upfront payments
included in contract liabilities at December 31, 2019 (in EUR k) |
| |
Revenue recognized
from upfront payments (in EUR k) |
| ||||||||||||
|
2018
|
| |
2019
|
| |||||||||||||||||
Eli Lilly and Company
|
| |
USD 50,000 (EUR 42,200)
|
| | | | 34,854 | | | | | | 3,516 | | | | | | 3,516 | | |
CRISPR
|
| | USD 3,000 (EUR 2,524) | | | | | 1,859 | | | | | | 310 | | | | | | 310 | | |
Boehringer Ingelheim
|
| | EUR 30,000 | | | | | 15,870 | | | | | | 2,035 | | | | | | 1,951 | | |
Genmab
|
| | USD 10,000 (EUR 8,937) | | | | | 8,937 | | | | | | — | | | | | | — | | |
Total | | | | | 61,520 | | | | | | 5,861 | | | | | | 5,777 | | |
| | |
January 1,
2018 |
| |
December 31,
2018 |
| |
December 31,
2019 |
| |||||||||
| | |
EUR k
|
| |
EUR k
|
| |
EUR k
|
| |||||||||
Trade receivables
|
| | | | 463 | | | | | | 5,476 | | | | | | 15,690 | | |
Contract assets
|
| | | | — | | | | | | 1,382 | | | | | | 1,463 | | |
Contract liabilities
|
| | | | 69,220 | | | | | | 70,360 | | | | | | 73,521 | | |
| | |
Year ended
|
| |||||||||
| | |
2018
EUR k |
| |
2019
EUR k |
| ||||||
Within one year
|
| | | | 5,777 | | | | | | 7,481 | | |
More than one year
|
| | | | 64,583 | | | | | | 66,040 | | |
Total | | | | | 70,360 | | | | | | 73,521 | | |
| | |
2018
|
| |
2019
|
| ||||||
| | |
EUR k
|
| |
EUR k
|
| ||||||
Personnel
|
| | | | (7,703) | | | | | | (9,855) | | |
Materials
|
| | | | (4,941) | | | | | | (7,542) | | |
Third-party services
|
| | | | (2,340) | | | | | | (7,268) | | |
Maintenance and lease
|
| | | | (1,758) | | | | | | (1,060) | | |
摊销折旧
|
| | | | (893) | | | | | | (2,038) | | |
Other
|
| | | | (109) | | | | | | (220) | | |
Total
|
| | | | (17,744) | | | | | | (27,983) | | |
| | |
2018
|
| |
2019
|
| ||||||
| | |
EUR k
|
| |
EUR k
|
| ||||||
Personnel
|
| | | | (581) | | | | | | (1,263) | | |
维护和租赁成本
|
| | | | (300) | | | | | | (167) | | |
摊销折旧
|
| | | | (95) | | | | | | (81) | | |
Other
|
| | | | (109) | | | | | | (243) | | |
Total | | | | | (1,085) | | | | | | (1,755) | | |
| | |
2018
|
| |
2019
|
| ||||||
| | |
EUR k
|
| |
EUR k
|
| ||||||
Materials
|
| | | | (5,867) | | | | | | (4,015) | | |
Personnel
|
| | | | (7,565) | | | | | | (14,385) | | |
摊销折旧
|
| | | | (1,143) | | | | | | (474) | | |
注册合法权利的专利和费用
|
| | | | (4,847) | | | | | | (4,551) | | |
Third-party services
|
| | | | (19,921) | | | | | | (18,626) | | |
Maintenance and lease
|
| | | | (1,156) | | | | | | (670) | | |
Other
|
| | | | (1,223) | | | | | | (521) | | |
Total | | | | | (41,722) | | | | | | (43,242) | | |
| | |
2018
|
| |
2019
|
| ||||||
| | |
EUR k
|
| |
EUR k
|
| ||||||
Personnel
|
| | | | (10,084) | | | | | | (31,645) | | |
维护和租赁成本
|
| | | | (3,239) | | | | | | (4,604) | | |
Third-party services
|
| | | | (4,006) | | | | | | (5,970) | | |
法律和其他专业服务
|
| | | | (4,078) | | | | | | (2,110) | | |
摊销折旧
|
| | | | (1,635) | | | | | | (2,182) | | |
Other
|
| | | | (2,247) | | | | | | (2,458) | | |
Total | | | | | (25,289) | | | | | | (48,969) | | |
| | |
2018
|
| |
2019
|
| ||||||
| | |
EUR k
|
| |
EUR k
|
| ||||||
政府机构和类似机构提供的补助金和其他费用报销
|
| | | | 808 | | | | | | 5,385 | | |
Other
|
| | | | — | | | | | | 202 | | |
Total
|
| | | | 808 | | | | | | 5,587 | | |
| | |
2018
|
| |
2019
|
| ||||||
| | |
EUR k
|
| |
EUR k
|
| ||||||
监事会换届
|
| | | | (343) | | | | | | (521) | | |
Other
|
| | | | (320) | | | | | | (30) | | |
Total
|
| | | | (663) | | | | | | (552) | | |
(in thousands of EUR)
|
| |
Software and
licenses |
| |
Advance
payments |
| |
Total
|
| |||||||||
Acquisition costs | | | | | | | | | | | | | | | | | | | |
As of January 1, 2018
|
| | | | 3,402 | | | | | | 235 | | | | | | 3,638 | | |
Additions
|
| | | | 5,314 | | | | | | 2 | | | | | | 5,317 | | |
As of December 31, 2018
|
| | | | 8,717 | | | | | | 238 | | | | | | 8,954 | | |
累计摊销和减值费用 | | | | | | | | | | | | | | | | | | | |
As of January 1, 2018
|
| | | | 1,545 | | | | | | — | | | | | | 1,545 | | |
Amortization
|
| | | | 1,197 | | | | | | — | | | | | | 1,197 | | |
As of December 31, 2018
|
| | | | 2,742 | | | | | | — | | | | | | 2,742 | | |
|
(in thousands of EUR)
|
| |
Software and
licenses |
| |
Advance
payments |
| |
Total
|
| |||||||||
Acquisition costs | | | | | | | | | | | | | | | | | | | |
As of January 1, 2019
|
| | | | 8,717 | | | | | | 238 | | | | | | 8,954 | | |
Additions
|
| | | | 738 | | | | | | 44 | | | | | | 782 | | |
Disposals
|
| | | | (6) | | | | | | — | | | | | | (6) | | |
As of December 31, 2019
|
| | | | 9,449 | | | | | | 282 | | | | | | 9,731 | | |
累计摊销和减值费用 | | | | | | | | | | | | | | | | | | | |
As of January 1, 2019
|
| | | | 2,742 | | | | | | — | | | | | | 2,742 | | |
Amortization
|
| | | | 1,295 | | | | | | — | | | | | | 1,295 | | |
Disposals
|
| | | | (4) | | | | | | — | | | | | | (4) | | |
As of December 31, 2019
|
| | | | 4,033 | | | | | | — | | | | | | 4,033 | | |
Carrying amount | | | | | | | | | | | | | | | | | | | |
As of January 1, 2018
|
| | | | 1,858 | | | | | | 235 | | | | | | 2,093 | | |
As of December 31, 2018
|
| | | | 5,975 | | | | | | 238 | | | | | | 6,213 | | |
As of December 31, 2019
|
| | | | 5,416 | | | | | | 282 | | | | | | 5,698 | | |
(in thousands of EUR)
|
| |
Buildings
|
| |
Technical
equipment and machines |
| |
Other
equipment, furniture and fixtures |
| |
Assets
under construction |
| |
Total
|
| |||||||||||||||
Acquisition costs | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
As of January 1, 2018
|
| | | | 5,398 | | | | | | 12,230 | | | | | | 4,665 | | | | | | 27,103 | | | | | | 49,397 | | |
Additions
|
| | | | 490 | | | | | | 953 | | | | | | 719 | | | | | | 7,244 | | | | | | 9,406 | | |
Disposals
|
| | | | — | | | | | | (150) | | | | | | (157) | | | | | | — | | | | | | (307) | | |
Reclassifications
|
| | | | — | | | | | | 1,303 | | | | | | 19 | | | | | | (1,323) | | | | | | — | | |
Currency translation
|
| | | | — | | | | | | — | | | | | | — | | | | | | 1 | | | | | | 1 | | |
As of December 31, 2018
|
| | | | 5,888 | | | | | | 14,336 | | | | | | 5,247 | | | | | | 33,025 | | | | | | 58,497 | | |
累计折旧和减值费用 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
As of January 1, 2018
|
| | | | 1,337 | | | | | | 4,610 | | | | | | 2,654 | | | | | | 7,120 | | | | | | 15,721 | | |
Depreciation
|
| | | | 371 | | | | | | 1,299 | | | | | | 890 | | | | | | — | | | | | | 2,559 | | |
Disposals
|
| | | | — | | | | | | (99) | | | | | | (157) | | | | | | — | | | | | | (255) | | |
As of December 31, 2018
|
| | | | 1,708 | | | | | | 5,810 | | | | | | 3,387 | | | | | | 7,120 | | | | | | 18,025 | | |
|
(in thousands of EUR)
|
| |
Buildings
|
| |
Technical
equipment and machines |
| |
Other
equipment, furniture and fixtures |
| |
Assets
under construction |
| |
Total
|
| |||||||||||||||
Acquisition costs | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
As of January 1, 2019
|
| | | | 5,888 | | | | | | 14,336 | | | | | | 5,247 | | | | | | 33,025 | | | | | | 58,497 | | |
Additions
|
| | | | 854 | | | | | | 2,152 | | | | | | 712 | | | | | | 7,435 | | | | | | 11,152 | | |
Disposals
|
| | | | (65) | | | | | | (319) | | | | | | (248) | | | | | | — | | | | | | (632) | | |
Reclassifications
|
| | | | 167 | | | | | | 883 | | | | | | 187 | | | | | | (1,237) | | | | | | — | | |
Currency translation
|
| | | | — | | | | | | — | | | | | | 3 | | | | | | 4 | | | | | | 6 | | |
As of December 31, 2019
|
| | | | 6,844 | | | | | | 17,051 | | | | | | 5,902 | | | | | | 39,226 | | | | | | 69,023 | | |
累计折旧和减值费用 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
As of January 1, 2019
|
| | | | 1,708 | | | | | | 5,810 | | | | | | 3,388 | | | | | | 7,120 | | | | | | 18,026 | | |
Depreciation
|
| | | | 779 | | | | | | 1,637 | | | | | | 899 | | | | | | — | | | | | | 3,315 | | |
Disposals
|
| | | | (37) | | | | | | (190) | | | | | | (164) | | | | | | — | | | | | | (392) | | |
Currency translation
|
| | | | — | | | | | | — | | | | | | 1 | | | | | | — | | | | | | 1 | | |
As of December 31, 2019
|
| | | | 2,449 | | | | | | 7,257 | | | | | | 4,123 | | | | | | 7,120 | | | | | | 20,949 | | |
Carrying amount | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
As of January 1, 2018
|
| | | | 4,061 | | | | | | 7,621 | | | | | | 2,011 | | | | | | 19,982 | | | | | | 33,675 | | |
As of December 31, 2018
|
| | | | 4,181 | | | | | | 8,526 | | | | | | 1,860 | | | | | | 25,904 | | | | | | 40,472 | | |
As of December 31, 2019
|
| | | | 4,395 | | | | | | 9,795 | | | | | | 1,779 | | | | | | 32,105 | | | | | | 48,075 | | |
| | |
2018
|
| |
2019
|
| ||||||
| | |
EUR k
|
| |
EUR k
|
| ||||||
Raw materials
|
| | | | 2,742 | | | | | | 6,177 | | |
Finished goods
|
| | | | — | | | | | | 14 | | |
Other
|
| | | | 209 | | | | | | 6 | | |
Total
|
| | | | 2,951 | | | | | | 6,197 | | |
| | |
2018
|
| |
2019
|
| ||||||
| | |
EUR k
|
| |
EUR k
|
| ||||||
Short-term investments
|
| | | | 39,024 | | | | | | 430 | | |
Other
|
| | | | 229 | | | | | | 1,028 | | |
Total | | | | | 39,253 | | | | | | 1,458 | | |
|
Series
|
| |
Shares
|
| |||
A
|
| | | | 3,114,021 | | |
B
|
| | | | 91,649,616 | | |
C
|
| | | | 1,929,628 | | |
Total
|
| | | | 96,693,265 | | |
| | |
2018
|
| |
2019
|
| ||||||
期初未结清
|
| | | | 7,972,425 | | | | | | 6,640,449 | | |
在此期间发放的许可证
|
| | | | — | | | | | | 665,389 | | |
在此期间过期
|
| | | | (1,331,976) | | | | | | — | | |
期末未偿债务
|
| | | | 6,640,449 | | | | | | 7,305,838 | | |
其中归属(和支出)
|
| | | | 6,640,449 | | | | | | 7,305,838 | | |
| | |
2018
|
| |
2019
|
| ||||||
| | |
EUR k
|
| |
EUR k
|
| ||||||
研发费用
|
| | | | 4,229 | | | | | | — | | |
一般和行政费用
|
| | | | 21 | | | | | | (6,074) | | |
Total | | | | | 4,250 | | | | | | (6,074) | | |
|
加权平均公允价值
|
| | | | EUR3.80 | | |
|
加权平均股价
|
| | | | EUR9.19 | | |
|
Exercise price (USD 6.21)
|
| | | | EUR5.64 | | |
|
Expected volatility (%)
|
| | | | 50.0% | | |
|
Expected life (years)
|
| | | | 1.16 | | |
|
Risk-free interest rate (%)
|
| | | | 1.77% | | |
|
期初未结清
|
| | | | — | | |
|
在此期间发放的许可证
|
| | | | 745,236 | | |
|
期末未偿债务
|
| | | | 745,236 | | |
|
Thereof vested
|
| | | | 175,397 | | |
|
Thereof expensed
|
| | | | 284,387 | | |
| | |
2019
|
| |||
| | |
EUR k
|
| |||
研发费用
|
| | | | (258) | | |
销售和分销费用
|
| | | | (743) | | |
一般和行政费用
|
| | | | (79) | | |
Total | | | | | (1,080) | | |
|
加权平均公允价值
|
| | | | EUR3.87 | | |
|
加权平均股价
|
| | | | EUR9.19 | | |
|
Exercise price (USD 8.27)
|
| | | | EUR7.50 | | |
|
Expected volatility (%)
|
| | | | 50.0% | | |
|
Expected life (years)
|
| | | | 4.77 | | |
|
Risk-free interest rate (%)
|
| | | | 1.71% | | |
|
期初未结清
|
| | | | — | | |
|
在此期间发放的许可证
|
| | | | 3,866,309 | | |
|
期末未偿债务
|
| | | | 3,866,309 | | |
|
Thereof vested
|
| | | | 2,819,120 | | |
|
Thereof expensed
|
| | | | 3,207,042 | | |
| | |
2019
|
| |||
| | |
EUR k
|
| |||
一般和行政费用
|
| | | | (12,409) | | |
Total | | | | | (12,409) | | |
| | |
2018
|
| |
2019
|
| ||||||
| | |
EUR k
|
| |
EUR k
|
| ||||||
Trade payables
|
| | | | (9,029) | | | | | | (5,331) | | |
License fees payable
|
| | | | (501) | | | | | | (537) | | |
其他负债
|
| | | | (1,383) | | | | | | (607) | | |
Total | | | | | (10,913) | | | | | | (6,475) | | |
| | |
2018
|
| |
2019
|
| ||||||
| | |
EUR k
|
| |
EUR k
|
| ||||||
Accrued bonuses
|
| | | | 1,903 | | | | | | 2,477 | | |
Accrued vacation
|
| | | | 682 | | | | | | 780 | | |
Outstanding invoices
|
| | | | 6,812 | | | | | | 3,478 | | |
Professional fees
|
| | | | 292 | | | | | | 578 | | |
来自政府机构和类似机构的赠款
|
| | | | 1,186 | | | | | | 4,148 | | |
Other
|
| | | | 271 | | | | | | 554 | | |
Total | | | | | 11,146 | | | | | | 12,015 | | |
| | |
2018
|
| |
2019
|
| ||||||
| | |
EUR k
|
| |
EUR k
|
| ||||||
Loss before tax
|
| | | | (71,131) | | | | | | (100,125) | | |
预期税收优惠(基于2019年和2018年29.13%的法定税率)
|
| | | | 20,744 | | | | | | 29,162 | | |
对前几年当期所得税的调整
|
| | | | 42 | | | | | | — | | |
集团税率和当地税率差异的影响
|
| | | | 10 | | | | | | 8 | | |
未确认税损结转的影响
|
| | | | (22,428) | | | | | | (22,836) | | |
无法识别DTA/DTL造成的影响
|
| | | | — | | | | | | — | | |
首次确认税损结转
|
| | | | 430 | | | | | | — | | |
用于纳税的不可抵扣费用
|
| | | | | | | | | | | | |
不可抵扣的股份支付对−的影响
|
| | | | 1,209 | | | | | | (5,698) | | |
当地贸易税(加计/扣减)产生的−效应
|
| | | | (65) | | | | | | (191) | | |
−其他不可扣除的费用
|
| | | | (53) | | | | | | (78) | | |
Other effects
|
| | | | — | | | | | | (114) | | |
有效税收优惠/(费用)
|
| | | | (110) | | | | | | 252 | | |
税损结转
|
| |
2018
|
| |
2019
|
| ||||||
| | |
EUR k
|
| |
EUR k
|
| ||||||
企业所得税未用税损
|
| | | | 330,753 | | | | | | 407,434 | | |
贸易税未用税损
|
| | | | 329,210 | | | | | | 405,123 | | |
2019
|
| |
less than
3 months EURk |
| |
3 to 12 months
EURk |
| |
1 to 5 years
EURk |
| |
> 5 years
EURk |
| |
Total
EURk |
| |||||||||||||||
Convertible loans
|
| | | | — | | | | | | — | | | | | | (83,940) | | | | | | — | | | | | | (83,940) | | |
Lease liabilities (Note 2)
|
| | | | (732) | | | | | | (1,985) | | | | | | (9,192) | | | | | | (5,086) | | | | | | (16,995) | | |
Other liabilities
|
| | | | — | | | | | | (12,015) | | | | | | (362) | | | | | | (167) | | | | | | (12,544) | | |
Trade and other payables
|
| | | | (5,938) | | | | | | (537) | | | | | | — | | | | | | — | | | | | | (6,475) | | |
Total | | | | | (6,670) | | | | | | (14,537) | | | | | | (93,494) | | | | | | (5,253) | | | | | | (119,954) | | |
|
2018
|
| |
less than
3 months EURk |
| |
3 to 12 months
EURk |
| |
1 to 5 years
EURk |
| |
> 5 years
EURk |
| |
Total EURk
|
| |||||||||||||||
融资租赁负债
|
| | | | (29) | | | | | | (48) | | | | | | — | | | | | | — | | | | | | (77) | | |
Other liabilities
|
| | | | — | | | | | | (11,146) | | | | | | (688) | | | | | | (175) | | | | | | (12,009) | | |
Trade and other payables
|
| | | | (10,378) | | | | | | (535) | | | | | | — | | | | | | — | | | | | | (10,913) | | |
Total | | | | | (10,407) | | | | | | (11,729) | | | | | | (688) | | | | | | (175) | | | | | | (22,999) | | |
2018
|
| |
less than
3 months EURk |
| |
3 to 12 months
EURk |
| |
1 to 5 years
EURk |
| |
> 5 years
EURk |
| |
Total EURk
|
| |||||||||||||||
经营租赁承诺额
|
| | | | — | | | | | | (84) | | | | | | (91) | | | | | | — | | | | | | (175) | | |
Rental agreements
|
| | | | (683) | | | | | | (2,576) | | | | | | (21,160) | | | | | | (23,589) | | | | | | (48,008) | | |
Total | | | | | (683) | | | | | | (2,660) | | | | | | (21,251) | | | | | | (23,589) | | | | | | (48,183) | | |
| | |
2019
(in thousands) |
| |||
现金和现金等价物
|
| |
22,608 EUR
|
| |
25,398 USD
|
|
贸易和其他应收账款
|
| |
9,458 EUR
|
| |
10,585 USD
|
|
Other receivables
|
| |
105 EUR
|
| |
93 GBP
|
|
| | |
84 EUR
|
| |
92 CHF
|
|
| | |
81 EUR
|
| |
91 USD
|
|
外币货币资产
|
| |
32,336 EUR
|
| | | |
Trade and other payables
|
| |
505 EUR
|
| |
567 USD
|
|
| | |
219 EUR
|
| |
186 GBP
|
|
| | |
10 EUR
|
| |
11 CHF
|
|
外币货币负债
|
| |
734 EUR
|
| | | |
| | |
2018
(in thousands) |
| |||
现金和现金等价物
|
| |
16,941 EUR
|
| |
19,398 USD
|
|
贸易和其他应收账款
|
| |
2,059 EUR
|
| |
3,374 USD
|
|
外币货币资产
|
| |
19,000 EUR
|
| |
22,772 USD
|
|
Trade and other payables
|
| |
8,002 EUR
|
| |
9,162 USD
|
|
| | |
132 EUR
|
| |
118 GBP
|
|
| | |
46 EUR
|
| |
51 CHF
|
|
外币货币负债
|
| |
8,180 EUR
|
| | | |
| 2018 (1 EUR= 1.1450 USD) | | | 2019 (1 EUR = 1.1234 USD) | |
| EUR 10,544k from USD 13,090k | | | EUR 30,656k from USD 34,400k | |
in thousands of EUR
|
| |
January 1,
2019 |
| |
Cash
flows |
| |
Reclassification
|
| |
New
leases |
| |
Accrued
interest |
| |
Foreign
Exchange Movements |
| |
December 31,
2019 |
| |||||||||||||||||||||
Convertible loans
|
| | | | — | | | | | | 69,889 | | | | | | (7,604) | | | | | | — | | | | | | 2,733 | | | | | | — | | | | | | 65,018 | | |
Lease liabilities
|
| | | | 15,810 | | | | | | (1,910) | | | | | | — | | | | | | 153 | | | | | | — | | | | | | 77 | | | | | | 14,130 | | |
融资负债总额
activities |
| | | | 15,810 | | | | | | 67,979 | | | | | | (7,604) | | | | | | 153 | | | | | | 2,733 | | | | | | 77 | | | | | | 79,148 | | |
in thousands of EUR
|
| |
January 1,
2018 |
| |
Changes from
financing cash flows |
| |
December 31,
2018 |
| |||||||||
Lease liabilities
|
| | | | 188 | | | | | | (112) | | | | | | 77 | | |
融资活动的总负债
|
| | | | 188 | | | | | | (112) | | | | | | 77 | | |
2019年密钥管理薪酬
|
| |
Management
Board |
| |
Supervisory
Board |
| ||||||
| | |
EUR k
|
| |
EUR k
|
| ||||||
Short-term benefits
|
| | | | 3,166 | | | | | | 521 | | |
Share-based payments
|
| | | | 18,483 | | | | | | — | | |
Total | | | | | 21,649 | | | | | | 521 | | |
2018年密钥管理薪酬
|
| |
Management
Board |
| |
Supervisory
Board |
| ||||||
| | |
EUR k
|
| |
EUR k
|
| ||||||
Short-term benefits
|
| | | | 2,195 | | | | | | 343 | | |
Total | | | | | 2,195 | | | | | | 343 | | |
| 1.1 | | | 承保协议格式。 | |
| 3.1 | | | CureVac N.V.公司章程表格(参考2020年8月10日提交的公司F-1表格附件3.1并入)。 | |
| 3.2 | | | CureVac N.V.管理委员会内部规则表格(通过参考2020年8月10日提交的公司F-1表格附件3.2并入)。 | |
| 3.3 | | | CureVac N.V.监事会内部规则表格(通过参考2020年8月10日提交的公司F-1表格附件3.3并入)。 | |
| 3.4 | | | 股票发行契约格式。 | |
| 3.5 | | | 若干股东与CureVac AG之间的投资和股东协议(通过参考2020年8月10日提交的公司F-1表格中的附件3.5合并而成)。 | |
| 3.6 | | | Kreditanstalt für Wiederaufbau、Dievini Hopp BioTechHolding GmbH&Co KG和Mr Dietmar Hopp之间的股东协议,日期为2020年6月16日(通过参考2020年8月10日提交的公司F-1表格中的附件3.6合并)。 | |
| 3.7 | | | Kreditanstalt Fur Wiederaufbau、Dievini Hopp BioTechHolding GmbH&Co KG和Mr Dietmar Hopp之间的关系协议,日期为2020年7月17日(通过引用2020年8月10日提交的公司F-1表格中的附件3.7合并)。 | |
| 4.1 | | | 注册权协议表格(通过参考2020年8月10日提交的公司F-1表格的附件4.1并入)。 | |
| 5.1 | | | CureVac荷兰律师NautaDutilh N.V.对普通股有效性的意见表格。 | |
| 8.1 | | | CureVac荷兰律师NautaDutilh N.V.对荷兰税务问题的意见。 | |
| 8.2 | | | 福尔克股份有限公司对德国税务问题的意见。 | |
| 8.3 | | | Davis Polk&Wardwell LLP对美国税务问题的看法。 | |
| 10.1 | | | CureVac AG和Genmab B.V.之间的合作和许可协议,日期为2019年12月19日(通过引用2020年8月10日提交的公司F-1表格的附件10.1并入)。† | |
| 10.2 | | | CureVac AG和CRISPR Treateutics AG之间的开发和许可协议,日期为2017年11月9日(通过引用2020年8月10日提交的公司F-1表格中的附件10.2并入)。† | |
| 10.3 | | | CureVac GmbH和勃林格-英格尔海姆国际有限公司之间的独家合作和许可协议,日期为2014年8月21日(通过参考2020年8月10日提交的公司F-1表格的附件10.3并入)。† | |
| 10.4 | | | CureVac GmbH和勃林格英格尔海姆国际有限公司之间独家合作和许可协议的第1号修正案,日期为2015年6月30日(通过引用2020年8月10日提交的公司F-1表格中的附件10.4并入)。† | |
| 10.5 | | | CureVac AG和勃林格英格尔海姆国际有限公司之间的独家合作和许可协议修正案2,日期为2016年8月1日(通过引用2020年8月10日提交的公司F-1表格的附件10.5并入)。† | |
| 10.6 | | | CureVac AG和勃林格英格尔海姆国际有限公司之间的独家合作和许可协议修正案3,日期为2019年8月8日(通过引用2020年8月10日提交的公司F-1表格中的附件10.6并入)。† | |
| 10.7 | | | 《全球准入承诺协议》,由比尔和梅琳达·盖茨基金会与CureVac GmbH签署,日期为2015年2月13日(并入本公司于2020年8月10日提交的F-1表格的附件10.7)。† | |
| 10.8 | | | 《比尔和梅林达·盖茨基金会与CureVac GmbH在临床前模型中对非活轮状病毒疫苗的RNA疫苗技术进行评估的最终协议和项目合作计划》,日期为2014年5月15日(通过引用2020年8月10日提交的公司F-1表格中的附件10.8合并而成)。† | |
| 10.9 | | | 防疫创新联盟和CureVac AG之间的框架合作协议,日期为2019年2月15日(通过参考2020年8月10日提交的公司F-1表格中的附件10.9并入)。† | |
| 10.10 | | | 2020年1月27日防疫创新联盟和CureVac股份公司之间的工作包声明(针对新型冠状病毒(2019-nCoV)制定CureVac暴发响应)(通过引用2020年8月10日提交的公司F-1表格附件10.10并入)。† | |
| 10.11 | | | CureVac AG和Acuitas Treateutics Inc.之间的开发和期权协议,日期为2016年4月29日(通过参考2020年8月10日提交的公司F-1表格中的附件10.11并入)。† | |
| 10.12 | | | CureVac AG和Acuitas Treateutics Inc.于2016年12月1日签订的开发和期权协议的副协议和修正案1(通过引用2020年8月10日提交的公司F-1表格的附件10.12并入)。† | |
| 10.13 | | | CureVac AG和特斯拉·格罗曼自动化有限公司之间的开发和知识产权协议,日期为2015年11月24日(通过引用附件10.13并入该公司于2020年8月10日提交的F-1表格)。† | |
| 10.14 | | | CureVac AG和Arcturus Treateutics Inc.于2018年1月1日签署的开发和期权协议(通过参考2020年8月10日提交的公司F-1表格中的附件10.14并入)。† | |
| 10.15 | | | CureVac AG和Arcturus Treateutics Inc.于2018年9月28日重新签署的开发和期权协议修正案(通过引用2020年8月10日提交的公司F-1表格的附件10.15并入)。† | |
| 10.16 | | | CureVac AG和Arcturus Treateutics Inc.于2019年7月24日签署的开发和期权协议第三修正案(通过引用2020年8月10日提交的公司F-1表格中的附件10.16并入)。† | |
| 10.17 | | | Dietmar Hopp先生和CureVac AG之间的可转换贷款,日期为2019年10月24日(通过引用附件10.17并入公司于2020年8月10日提交的F-1表格)。 | |
| 10.18 | | | CureVac AG和耶鲁大学于2019年7月1日签订的合作研究协议(通过引用附件10.18并入该公司于2020年8月10日提交的F-1表格)。† | |
| 10.19 | | | CureVac股份公司和谢彭斯眼科研究所公司于2019年3月15日签署的赞助研究协议(通过引用附件10.19并入该公司于2020年8月10日提交的F-1表格)。† | |
| 10.20 | | | CureVac股份公司和谢彭斯眼科研究所公司于2019年5月19日签署的赞助研究协议第一修正案(通过引用2020年8月10日提交的公司F-1表格中的附件10.20并入)。† | |
| 10.21 | | | CureVac Real Estate GmbH和TechnologieParks Tübingen-Rutlingen GmbH之间的商业场所租赁合同,日期为2018年1月31日(通过参考2020年8月10日提交的公司F-1表格中的附件10.21并入)。 | |
| 10.22 | | | CureVac Real Estate GmbH和Fränkel Immobilien-Service GmbH之间的租赁合同,日期为2018年6月6日(通过参考2020年8月10日提交的公司F-1表格中的10.22并入)。 | |
| 10.23 | | | CureVac Real Estate GmbH和Fränkel Immobilien-Service GmbH于2018年7月23日签订的租赁合同补充文件(通过引用2020年8月10日提交的公司F-1表格中的附件10.23并入)。 | |
| 10.24 | | | CureVac Real Estate GmbH和Fränkel Immobilien-Service GmbH之间租赁合同的第二份补充文件,日期为2018年8月20日(通过引用2020年8月10日提交的公司F-1表格中的附件10.24并入)。 | |
| 10.25 | | | CureVac Real Estate GmbH与HSB Vermietungs-und Verpachtungs-GmbH&Co.KG租赁合同的第三份补充文件,日期为2018年11月5日(通过引用2020年8月10日提交的公司F-1表格附件10.25并入)。 | |
| 10.26 | | | CureVac Real Estate GmbH与HSB Vermietungs-und Verpachtungs-GmbH&Co.Kg租赁合同的第四份补充文件,日期为2019年10月22日(通过引用2020年8月10日提交的公司F-1表格附件10.26并入)。 | |
| 10.27 | | | CureVac N.V.与监事会或管理委员会成员之间的赔偿协议格式(通过参考2020年8月10日提交的公司F-1表格附件10.27并入)。 | |
| 10.28 | | | CureVac N.V.长期激励计划(通过参考2020年8月10日提交的公司F-1表格的附件10.28并入)。 | |
| 10.29 | | | CureVac虚拟股票计划(在2020年8月10日提交的公司F-1表格中参考附件10.29并入)。 | |
| 10.30 | | | CureVac AG、CureVac Real Estate GmbH和礼来公司之间的终止协议,日期为2020年6月26日(通过参考2020年8月10日提交的公司F-1表格中的附件10.30并入)。† | |
| 10.31 | | | Dietmar Hopp先生与CureVac AG之间的可转换贷款协议修正案,日期为2020年6月25日(通过引用附件10.31并入公司于2020年8月10日提交的F-1表格)。 | |
| 10.32 | | | CureVac AG和Genmab B.V.之间的合作和许可协议第一修正案,日期为2020年7月2日(通过引用2020年8月10日提交的公司F-1表格中的附件10.32并入)。† | |
| 10.33 | | | CureVac AG和葛兰素史克生物公司之间的合作和许可协议,日期为2020年7月15日(通过引用2020年8月10日提交的公司F-1表格中的附件10.33并入)。† | |
| 10.34 | | | CureVac AG和Acuitas Treateutics Inc.于2020年7月10日签署的开发和期权协议修正案2(通过引用2020年8月10日提交的公司F-1表格的附件10.34并入)。† | |
| 10.35 | | | 欧洲投资银行和CureVac房地产有限公司之间的融资费用函,日期为2020年6月27日(通过引用2020年8月10日提交的公司F-1表格的附件10.35并入)。† | |
| 10.36 | | | 欧洲投资银行与CureVac房地产有限公司之间的融资协议,日期为2020年6月27日(通过引用附件10.36并入该公司于2020年8月10日提交的F-1表格)。† | |
| 10.37 | | | 欧洲投资银行和CureVac AG之间的担保协议,日期为2020年6月27日(通过引用附件10.37并入该公司于2020年8月10日提交的F-1表格)。† | |
| 10.38 | | | 关于CureVac AG与比尔和梅林达·盖茨基金会之间的全球准入承诺协议与2020年7月15日CureVac AG与葛兰素史克生物公司之间的合作和许可协议(通过引用2020年8月10日提交的公司F-1表格中的附件10.38并入)的书面协议。† | |
| 10.39 | | | CureVac AG、CureVac B.V.和比尔和梅琳达·盖茨基金会于2020年7月15日签订的《全球接入承诺协议第一修正案和联合声明》(通过引用2020年8月10日提交的公司F-1表格的附件10.39合并而成)。 | |
| 10.40 | | | 比尔和梅琳达·盖茨基金会与CureVac AG于2020年7月15日签署的《全球准入承诺协议第二修正案》(通过引用附件10.40并入该公司于2020年8月10日提交的F-1表格)。† | |
| 10.41 | | | CureVac N.V.长期激励计划表格(参考2020年8月10日提交的公司F-1表格附件10.41并入)。 | |
| 10.42 | | | CureVac AG和CRISPR Treeutics,AG之间的开发和许可协议的第一修正案,自2017年11月9日起生效。 | |
| 10.43 | | | 比尔和梅林达·盖茨基金会与CureVac AG之间最终协议1的修正案4,2020年11月3日生效。 | |
| 10.44 | | | 几个股东和CureVac N.V.之间的投资和股东协议附录,日期为2020年6月16日。 | |
| 10.45 | | | CureVac AG和欧盟委员会于2020年11月30日签订的预购协议(通过引用2021年1月19日提交的公司Form 6-K中的附件99.1并入)。 | |
| 10.46 | | | Genmab B.V.和CureVac AG之间的协作和许可协议第二修正案,日期为2019年12月19日。† | |
| 10.47 | | | Acuitas Treateutics Inc.和CureVac AG之间的开发和选项协议修正案三,日期为2020年12月24日。† | |
| 10.48 | | | 2020年12月11日,防疫创新联盟和CureVac AG之间的框架合作协议第一修正案。 | |
| 21.1 | | | 子公司清单(参照2020年8月10日提交的公司F-1表格中的附件21.1合并)。 | |
| 23.1 | | | 安永会计师事务所同意。 | |
| 23.2 | | | NautaDutilh N.V.同意(见附件5.1和8.1)。 | |
| 23.3 | | | 经Falk GmbH&Co KG同意(见附件8.2)。 | |
| 23.4 | | | 经Davis Polk&Wardwell LLP同意(包含在附件8.3中)。 | |
| 24.1 | | | Powers of attorney. | |
|
Name
|
| |
Title
|
|
|
/s/ Franz-Werner Haas, LLD, LLM
Franz-Werner Haas, LLD, LLM
|
| | 首席执行官 | |
|
/s/ Pierre Kemula, B.Sc.
Pierre Kemula, B.Sc.
|
| | 首席财务官 | |
|
/s/ Florian von der Mülbe, Ph.D., MBA
Florian von der Mülbe, Ph.D., MBA
|
| | 首席生产官 | |
|
/s/ Mariola Fotin-Mleczek, Ph.D
Mariola Fotin-Mleczek, Ph.D
|
| | 首席技术官 | |
|
/s/ Igor Splawski, Ph.D., MSc
Igor Splawski, Ph.D., MSc
|
| | 首席科学官 | |
|
/s/ Antony Blanc
Antony Blanc
|
| | 首席商务官兼首席商务官 | |
|
/s/ Baron Jean Stéphenne, MSc, MBA
Baron Jean Stéphenne, MSc, MBA
|
| | 董事董事长兼监事 | |
|
/s/ Ralf Clemens, MD, Ph.D.
Ralf Clemens, MD, Ph.D.
|
| | 监管董事 | |
|
Name
|
| |
Title
|
|
|
/s/ Mathias Hotum, Ph.D.
Mathias Hotum, Ph.D.
|
| | 监管董事 | |
|
/s/ Hans Christoph Tanner, Ph.D.
Hans Christoph Tanner, Ph.D.
|
| | 监管董事 | |
|
/s/Friedrich von Bohlen and Halbach,Ph.D.
弗里德里希·冯·博伦和哈尔巴赫博士
|
| | 董事副董事长兼监事 | |
|
/s/ Timothy M. Wright, MD
Timothy M. Wright, MD
|
| | 监管董事 | |
|
/s/ Craig A. Tooman, MBA
Craig A. Tooman, MBA
|
| | 监管董事 | |
|
/s/ Viola Bronsema, Ph.D.
Viola Bronsema, Ph.D.
|
| | 监管董事 | |